

Genpact LTD  
Form 10-Q  
November 07, 2014  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**Form 10-Q**

(Mark One)

**Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
For the Quarterly Period ended September 30, 2014**

**Or**

**Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
For the Transition Period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission file number: 001-33626**

**GENPACT LIMITED**  
**(Exact name of registrant as specified in its charter)**

**Bermuda**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**98-0533350**  
**(I.R.S. Employer**  
**Identification No.)**

**Canon s Court**  
**22 Victoria Street**  
**Hamilton HM12**  
**Bermuda**  
**(441) 295-2244**

**(Address, including zip code, and telephone number, including area code, of registrant s principal executive office)**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of accelerated filer, large accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of the registrant s common shares, par value \$0.01 per share, outstanding as of October 30, 2014 was 216,589,934.



**Table of Contents****TABLE OF CONTENTS**

<b>Item No.</b>		<b>Page No.</b>
<b>PART I</b>	<b>Financial Statements</b>	
1.	Unaudited Consolidated Financial Statements	
	<u>Consolidated Balance Sheets as of December 31, 2013 and September 30, 2014</u>	1
	<u>Consolidated Statements of Income for the three months and nine months ended September 30, 2013 and 2014</u>	3
	<u>Consolidated Statements of Comprehensive Income (Loss) for the three months and nine months ended September 30, 2013 and 2014</u>	4
	<u>Consolidated Statements of Equity for the nine months ended September 30, 2013 and 2014</u>	5
	<u>Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and 2014</u>	7
	<u>Notes to the Consolidated Financial Statements</u>	8
2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	29
3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	44
4.	<u>Controls and Procedures</u>	44
<b>PART II</b>	<b>Other Information</b>	
1.	<u>Legal Proceedings</u>	45
1A.	<u>Risk Factors</u>	45
2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	45
3.	<u>Defaults upon Senior Securities</u>	45
5.	<u>Other Information</u>	46
6.	<u>Exhibits</u>	46
	<b><u>SIGNATURES</u></b>	47

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Consolidated Balance Sheets****(Unaudited)****(In thousands, except per share data and share count)**

	Notes	As of December 31, 2013	As of September 30, 2014
<b>Assets</b>			
<i>Current assets</i>			
Cash and cash equivalents	4	\$ 571,276	\$ 399,199
Accounts receivables, net	5	505,117	533,793
Short term deposits			25,000
Deferred tax assets	22	60,638	44,382
Prepaid expenses and other current assets	8	139,113	203,684
<b>Total current assets</b>		<b>\$ 1,276,144</b>	<b>\$ 1,206,058</b>
Property, plant and equipment, net	9	173,204	176,173
Deferred tax assets	22	89,305	61,933
Investment in equity affiliates		384	471
Intangible assets, net	10	99,116	114,925
Goodwill	10	953,849	1,055,978
Other assets		97,365	123,846
<b>Total assets</b>		<b>\$ 2,689,367</b>	<b>\$ 2,739,384</b>

See accompanying notes to the Consolidated Financial Statements.

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Consolidated Balance Sheets****(Unaudited)****(In thousands, except per share data and share count)**

	Notes	As of December 31, 2013	As of September 30, 2014
<b>Liabilities and equity</b>			
<i>Current liabilities</i>			
Short-term borrowings	11	\$	\$ 165,000
Current portion of long-term debt	12	4,263	4,281
Current portion of capital lease obligations		1,405	1,540
Accounts payable		18,412	17,215
Income taxes payable	22	15,007	56,339
Deferred tax liabilities	22	614	586
Accrued expenses and other current liabilities	13	421,992	426,532
<b>Total current liabilities</b>		<b>\$ 461,693</b>	<b>\$ 671,493</b>
Long-term debt, less current portion	12	653,601	650,383
Capital lease obligations, less current portion		2,657	2,844
Deferred tax liabilities	22	4,464	4,832
Other liabilities		242,884	161,301
<b>Total liabilities</b>		<b>\$ 1,365,299</b>	<b>\$ 1,490,853</b>
<b>Shareholders equity</b>			
Preferred shares, \$0.01 par value, 250,000,000 authorized, none issued			
Common shares, \$0.01 par value, 500,000,000 authorized, 231,262,576 and 216,580,092 issued and outstanding as of December 31, 2013 and September 30, 2014, respectively		2,310	2,162
Additional paid-in capital		1,268,344	1,286,886
Retained earnings		511,699	352,954
Accumulated other comprehensive income (loss)		(459,614)	(393,471)
<b>Genpact Limited shareholders equity</b>		<b>\$ 1,322,739</b>	<b>\$ 1,248,531</b>
Noncontrolling interest		1,329	
<b>Total equity</b>		<b>\$ 1,324,068</b>	<b>\$ 1,248,531</b>
Commitments and contingencies	24		
<b>Total liabilities and equity</b>		<b>\$ 2,689,367</b>	<b>\$ 2,739,384</b>

See accompanying notes to the Consolidated Financial Statements.

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Consolidated Statements of Income****(Unaudited)****(In thousands, except per share data and share count)**

		Three months ended September 30,		Nine months ended September 30,	
	Notes	2013	2014	2013	2014
<b>Net revenues</b>					
Net revenues from services	23	\$ 534,886	\$ 588,107	\$ 1,573,538	\$ 1,677,908
<b>Cost of revenue</b>					
Services	18, 23	329,289	354,475	973,729	1,018,889
<b>Gross profit</b>		<b>\$ 205,597</b>	<b>\$ 233,632</b>	<b>\$ 599,809</b>	<b>\$ 659,019</b>
<i>Operating expenses:</i>					
Selling, general and administrative expenses	19, 23	117,005	153,148	348,632	418,361
Amortization of acquired intangible assets	10	5,867	7,989	17,603	20,617
Other operating (income) expense, net	20	(3,232)	(372)	(4,320)	(3,124)
<b>Income from operations</b>		<b>\$ 85,957</b>	<b>\$ 72,867</b>	<b>\$ 237,894</b>	<b>\$ 223,165</b>
Foreign exchange (gains) losses, net		(10,817)	4,671	(24,619)	12,093
Other income (expense), net	21	(3,454)	(6,439)	(19,104)	(19,477)
<b>Income before equity-method investment activity, net and income tax expense</b>		<b>\$ 93,320</b>	<b>\$ 61,757</b>	<b>\$ 243,409</b>	<b>\$ 191,595</b>
Equity-method investment activity, net		(32)	(33)	(139)	(87)
<b>Income before income tax expense</b>		<b>\$ 93,352</b>	<b>\$ 61,790</b>	<b>\$ 243,548</b>	<b>\$ 191,682</b>
Income tax expense	22	21,921	15,124	58,403	45,263
<b>Net income</b>		<b>\$ 71,431</b>	<b>\$ 46,666</b>	<b>\$ 185,145</b>	<b>\$ 146,419</b>
Net income attributable to noncontrolling interest		1,169	13	4,270	169
<b>Net income attributable to Genpact Limited shareholders</b>		<b>\$ 70,262</b>	<b>\$ 46,653</b>	<b>\$ 180,875</b>	<b>\$ 146,250</b>
	17	\$ 70,262	\$ 46,653	\$ 180,875	\$ 146,250

Net income available to Genpact Limited common shareholders				
Earnings per common share attributable to Genpact Limited common shareholders				
	17			
Basic	\$	0.31	\$	0.22
Diluted	\$	0.30	\$	0.21
			\$	0.79
			\$	0.66
			\$	0.77
			\$	0.65
Weighted average number of common shares used in computing earnings per common share attributable to Genpact Limited common shareholders				
Basic	230,057,508	216,472,908	228,840,746	222,036,262
Diluted	236,336,924	220,535,530	235,095,660	226,440,350

See accompanying notes to the Consolidated Financial Statements.

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Consolidated Statements of Comprehensive Income (Loss)****(Unaudited)****(In thousands)**

	<b>Three months ended September 30,</b>				<b>Nine months ended September 30,</b>			
	<b>2013</b>		<b>2014</b>		<b>2013</b>		<b>2014</b>	
	Genpact Limited Shareholders	Non controlling interest	Genpact Limited Shareholders	Non controlling interest	Genpact Limited Shareholders	Non controlling interest	Genpact Limited Shareholders	Non controlling interest
Net Income	\$ 70,262	\$ 1,169	\$ 46,653	\$ 13	\$ 180,875	\$ 4,270	\$ 146,250	\$ 169
Other comprehensive income:								
Currency translation adjustments	(44,370)	31	(30,386)	(1)	(136,108)	65	(11,395)	(11)
Net income (loss) on cash flow hedging derivatives, net of taxes (Note 7)	(33,963)		14,757		(63,411)		77,337	
Retirement benefits, net of taxes			45				201	
Other comprehensive income (loss)	\$(78,333)	\$ 31	\$(15,584)	\$ (1)	\$(199,519)	\$ 65	\$ 66,143	\$ (11)
Comprehensive income (loss)	\$ (8,071)	\$ 1,200	\$ 31,069	\$ 12	\$ (18,644)	\$ 4,335	\$ 212,393	\$ 158

See accompanying notes to the Consolidated Financial Statements.

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Consolidated Statements of Equity****(Unaudited)****(In thousands, except share count)**

	Genpact Limited Shareholders			Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling interest	Total Equity
	Common shares		Additional Paid-in Capital				
	No. of Shares	Amount					
<b>Balance as of January 1, 2013</b>	<b>225,480,172</b>	<b>\$ 2,253</b>	<b>\$ 1,202,448</b>	<b>\$ 281,982</b>	<b>\$ (318,272)</b>	<b>\$ 3,370</b>	<b>\$ 1,171,781</b>
Issuance of common shares on exercise of options (Note 15)	3,784,851	38	33,979				34,017
Issuance of common shares under the employee stock purchase plan (Note 15)	81,040	1	1,371				1,372
Net settlement on vesting of restricted share units (Note 15)	305,382	3	(2,538)				(2,535)
Net settlement on vesting of performance units (Note 15)	496,112	5	(5,069)				(5,064)
Disposition of noncontrolling interest						(1,055)	(1,055)
Distribution to noncontrolling interest						(4,614)	(4,614)
Stock-based compensation expense (Note 15)			21,931				21,931
Comprehensive income:							
Net income				180,875		4,270	185,145
Other comprehensive income					(199,519)	65	(199,454)
<b>Balance as of September 30, 2013</b>	<b>230,147,557</b>	<b>\$ 2,300</b>	<b>\$ 1,252,122</b>	<b>\$ 462,857</b>	<b>\$ (517,791)</b>	<b>\$ 2,036</b>	<b>\$ 1,201,524</b>

See accompanying notes to the Consolidated Financial Statements.



Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Consolidated Statements of Equity****(Unaudited)****(In thousands, except share count)**

	Genpact Limited Shareholders			Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling interest	Total Equity
	Common shares		Additional Paid-in Capital				
	No. of Shares	Amount					
<b>Balance as of January 1, 2014</b>	<b>231,262,576</b>	<b>\$ 2,310</b>	<b>\$ 1,268,344</b>	<b>\$ 511,699</b>	<b>\$ (459,614)</b>	<b>\$ 1,329</b>	<b>\$ 1,324,068</b>
Net settlement on issuance of common shares on exercise of options (Note 15)	1,448,044	14	4,008				4,022
Issuance of common shares under the employee stock purchase plan (Note 15)	117,305	1	1,792				1,793
Net settlement on vesting of restricted share units (Note 15)	131,070	1	(911)				(910)
Net settlement on vesting of performance units (Note 15)	913,939	9	(6,500)				(6,491)
Stock purchased and retired	(17,292,842)	(173)		(302,452)			(302,625)
Expenses related to stock purchase				(2,543)			(2,543)
Distribution to noncontrolling interest						(1,487)	(1,487)
Stock-based compensation expense (Note 15)			20,153				20,153
Comprehensive income:							
Net income				146,250		169	146,419
Other comprehensive income					66,143	(11)	66,132
<b>Balance as of September 30, 2014</b>	<b>216,580,092</b>	<b>\$ 2,162</b>	<b>\$ 1,286,886</b>	<b>\$ 352,954</b>	<b>\$ (393,471)</b>		<b>\$ 1,248,531</b>

See accompanying notes to the Consolidated Financial Statements.

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Consolidated Statements of Cash Flows****(Unaudited)****(In thousands)**

	<b>Nine months ended September 30,</b>	
	<b>2013</b>	<b>2014</b>
<b>Operating activities</b>		
Net income attributable to Genpact Limited shareholders	\$ 180,875	\$ 146,250
Net income attributable to noncontrolling interest	4,270	169
<b>Net income</b>	<b>\$ 185,145</b>	<b>\$ 146,419</b>
<i>Adjustments to reconcile net income to net cash provided by (used for) operating activities:</i>		
Depreciation and amortization	40,270	37,784
Amortization of debt issue costs (including loss on extinguishment of debt)	5,215	2,425
Amortization of acquired intangible assets	17,603	20,617
Reserve for doubtful receivables	8,919	2,322
Unrealized (gain) loss on revaluation of foreign currency asset/liability	(5,646)	4,873
Equity-method investment activity, net	(139)	(87)
Stock-based compensation expense	21,931	20,153
Deferred income taxes	4,194	(6,583)
Others, net	5,872	1,133
<i>Change in operating assets and liabilities:</i>		
Increase in accounts receivables	(30,613)	(24,328)
Increase in other assets	(35,014)	(65,973)
Decrease in accounts payable	(797)	(5,563)
Increase (Decrease) in other liabilities	(20,826)	5,125
Increase in income taxes payable	37,103	40,486
<b>Net cash provided by operating activities</b>	<b>\$ 233,217</b>	<b>\$ 178,803</b>
<b>Investing activities</b>		
Purchase of property, plant and equipment	(37,061)	(48,192)
Proceeds from sale of property, plant and equipment	2,996	550
Short term deposits placed	(55,259)	(25,000)
Redemption of short term deposits	51,955	
Payment for business acquisitions, net of cash acquired	(49,235)	(123,701)
Proceeds from divestiture of business, net of cash divested	(1,049)	
<b>Net cash used for investing activities</b>	<b>\$ (87,653)</b>	<b>\$ (196,343)</b>
<b>Financing activities</b>		
Repayment of capital lease obligations	(1,284)	(1,525)

Edgar Filing: Genpact LTD - Form 10-Q

Proceeds from long-term debt	121,410	
Repayment of long-term debt	(121,410)	(5,062)
Proceeds from Short-term borrowings	35,000	195,000
Repayment of Short-term borrowings	(115,000)	(30,000)
Proceeds from issuance of common shares under stock-based compensation plans	35,389	11,866
Payment for net settlement of stock-based awards	(7,599)	(15,174)
Payment of earn-out and deferred consideration	(3,868)	(1,088)
Cost incurred in relation to debt amendment and refinancing	(8,104)	
Distribution to noncontrolling interest	(4,614)	(1,487)
Expenses related to stock purchase		(2,543)
Stock purchased and retired		(302,625)
<b>Net cash used for financing activities</b>	<b>\$ (70,080)</b>	<b>\$ (152,638)</b>
Effect of exchange rate changes	(53,214)	(1,899)
Net increase (decrease) in cash and cash equivalents	75,484	(170,178)
Cash and cash equivalents at the beginning of the period	459,228	571,276
<b>Cash and cash equivalents at the end of the period</b>	<b>\$ 481,498</b>	<b>\$ 399,199</b>
<b>Supplementary information</b>		
Cash paid during the period for interest	\$ 25,484	\$ 20,152
Cash paid during the period for income taxes	\$ 52,805	\$ 64,176
Property, plant and equipment acquired under capital lease obligations	\$ 1,933	\$ 1,840

See accompanying notes to the Consolidated Financial Statements.

---

**Table of Contents**

**GENPACT LIMITED AND ITS SUBSIDIARIES**

**Notes to the Consolidated Financial Statements**

**(Unaudited)**

**(In thousands, except per share data and share count)**

**1. Organization**

The Company designs, transforms, and runs intelligent business operations, including those that are complex and specific to a set of chosen industries. The result is advanced operating models that foster growth and manage cost, risk, and compliance across a range of functions such as finance and procurement, financial services account servicing, claims management, regulatory affairs, and industrial asset optimization. The Company's Smart Enterprise Processes (SEPSM) proprietary framework integrates effective technology and data-driven insight into the fabric of enterprise processes to help its clients be more competitive. The Company's hundreds of long-term clients include more than one-fourth of the Fortune Global 500. The Company's clients attribute much of its success to its unique history behind its passion for process and operational excellence is the Lean and Six Sigma heritage of a former General Electric division that has served GE businesses for more than 16 years.

Prior to December 30, 2004, the business of the Company was conducted through various entities and divisions of the General Electric Company (GE). On December 30, 2004, in a series of transactions referred to as the 2004 Reorganization, GE transferred such operations to the Company. In August 2007, the Company completed an initial public offering of its common shares, pursuant to which the Company and certain of its existing shareholders each sold 17,647,059 shares. On March 24, 2010, the Company completed a secondary offering of its common shares pursuant to which GE's shareholding in the Company decreased to 9.1% and it ceased to be a significant shareholder, although it continued to be a related party. During the year ended December 31, 2012, GE's shareholding declined to less than 5.0%, as a result of which GE is no longer considered a related party.

On December 14, 2012, a secondary offering of the Company's common shares by affiliates of General Atlantic (GA) and Oak Hill Capital Partners (OH) was completed. Upon the completion of the secondary offering, GA and OH each owned approximately 2.4% of the Company's common shares outstanding, and they ceased to be significant shareholders and related parties.

*2012 Recapitalization*

On August 1, 2012, affiliates of GA and OH entered into an agreement to sell 67,750,678 common shares of the Company to Glory Investments A Limited, formerly known as South Asia Private Investments, an affiliate of Bain Capital Investors, LLC (Bain Capital). On October 25, 2012, Bain Capital and its affiliated assignees, along with two additional co-investors (RGIP, LLC, an investor in certain investment funds which are affiliated with Bain Capital, and Twickenham Investment Private Limited, an affiliate of the Government of Singapore Investment Corporation Private Limited), completed the purchase of the Company's common shares covered by the share purchase agreement.

On August 30, 2012, the Company terminated its previous credit facility of \$380,000 and entered into a new credit facility of \$925,000. Net proceeds from the credit facility along with cash on hand were partially used to fund the payment of a special cash dividend in the amount of \$2.24 per share, or \$501,620 in aggregate, which was declared by the Company's board of directors on August 30, 2012, and paid on September 24, 2012 to holders of record as of September 10, 2012. The share purchase transaction described above, the entry into a new credit facility and the

payment of the special cash dividend are referred to collectively as the 2012 Recapitalization .

**Table of Contents**

**GENPACT LIMITED AND ITS SUBSIDIARIES**

**Notes to the Consolidated Financial Statements**

**(Unaudited)**

**(In thousands, except per share data and share count)**

**2. Summary of significant accounting policies**

*(a) Basis of preparation and principles of consolidation*

The unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q. Accordingly, they do not include certain information and note disclosures required by generally accepted accounting principles for annual financial reporting and should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.

The unaudited interim consolidated financial statements reflect all adjustments that management considers necessary for a fair presentation of the results of operations for these periods. The results of operations for the interim periods are not necessarily indicative of the results for the full year.

The accompanying unaudited interim consolidated financial statements have been prepared on a consolidated basis and reflect the financial statements of Genpact Limited and all of its subsidiaries that are more than 50% owned and controlled. When the Company does not have a controlling interest in an entity but exerts significant influence on the entity, the Company applies the equity method of accounting. All intercompany transactions and balances are eliminated in consolidation.

The noncontrolling interest disclosed in the accompanying unaudited interim consolidated financial statements represents the noncontrolling partners' interest in the operation of Genpact Netherlands B.V. and the profits or losses associated with such noncontrolling interest. The noncontrolling partners of Genpact Netherlands B.V. are individually liable for the tax obligations on their shares of profit as it is a partnership and, accordingly, noncontrolling interest relating to Genpact Netherlands B.V. has been computed prior to tax and disclosed accordingly in the unaudited interim Consolidated Statements of Income. During the quarter ended September 30, 2014, the Company purchased such noncontrolling interest, as a result of which the Company has 100% control of the partnership.

*(b) Use of estimates*

The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment, the carrying amount of property, plant and equipment, intangibles and goodwill, reserves for doubtful receivables, valuation allowances for deferred tax assets, the valuation of derivative financial instruments, measurements of stock-based compensation, assets and obligations related to employee benefits, and income tax uncertainties and other

contingencies. Management believes that the estimates used in the preparation of the consolidated financial statements are reasonable. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Any changes in estimates are adjusted prospectively in the Company's consolidated financial statements.

*(c) Business combinations, goodwill and other intangible assets*

The Company accounts for its business combinations using acquisition method of accounting in accordance with ASC 805, Business Combinations, by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any noncontrolling interest in the acquired business, measured at their acquisition date fair values. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value as of each reporting date until the contingency is resolved. Changes in fair value are recognized in earnings. All assets and liabilities of the acquired businesses, including goodwill, are assigned to reporting units. Acquisition related costs are expensed as incurred under Selling, General and Administrative Expenses.

Goodwill represents the cost of acquired businesses in excess of the fair value of identifiable tangible and intangible net assets purchased. Goodwill is not amortized but is tested for impairment at least on an annual basis on December 31, based on a number of factors, including operating results, business plans and future cash flows. The Company performs an assessment of qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Based on the assessment of events or circumstances, the Company performs the quantitative assessment of goodwill impairment if it determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, based on the quantitative impairment analysis, the carrying value of the goodwill of the reporting unit exceeds the fair value of that goodwill, an impairment loss is recognized in an amount equal to the excess. In addition, the Company performs the qualitative assessment of goodwill impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. See Note 10 for information and related disclosures.

**Table of Contents****GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****2. Summary of significant accounting policies (Continued)**

Intangible assets acquired individually or with a group of other assets or in a business combination are carried at cost less accumulated amortization based on their estimated useful lives as follows:

Customer-related intangible assets	1-14 years
Marketing-related intangible assets	1-10 years
Contract-related intangible assets	1 year
Other intangible assets	3-9 years

Intangible assets are amortized over their estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are consumed or otherwise realized.

In business combinations, where the fair value of identifiable tangible and intangible net assets purchased exceeds the cost of the acquired business, the Company recognizes the resulting gain under Other operating (income) expense, net in the Consolidated Statements of Income.

*(d) Financial instruments and concentration of credit risk*

Financial instruments that potentially subject the Company to concentration of credit risk are reflected principally in cash and cash equivalents, short term deposits, derivative financial instruments and accounts receivable. The Company places its cash and cash equivalents and derivative financial instruments with corporations and banks with high investment grade ratings, limits the amount of credit exposure with any one corporation or bank and conducts ongoing evaluations of the creditworthiness of the corporations and banks with which it does business. To reduce its credit risk on accounts receivable, the Company conducts ongoing credit evaluations of its clients. GE accounted for 28% and 25% of receivables as of December 31, 2013 and September 30, 2014, respectively. GE accounted for 23% and 21% of revenues for the nine months ended September 30, 2013 and 2014, respectively, and for 22% and 20% of revenues for the three months ended September 30, 2013 and 2014, respectively.

*(e) Recently adopted accounting pronouncements*

The authoritative bodies release standards and guidance which are assessed by management for impact on the Company's consolidated financial statements.

The following recently released accounting standards have been adopted by the Company. Adoption of these standards did not have a material impact on the Company's consolidated results of operations, cash flows, financial position or disclosures:

Effective January 1, 2014, the Company adopted FASB ASU 2013-05, Foreign Currency Matters (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon De-recognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity ( ASU 2013-05 ). This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided.

Effective January 1, 2014, the Company adopted FASB ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists ( ASU 2013-11 ). This new guidance requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets.

*(f) Reclassification*

Certain reclassifications have been made in the consolidated financial statements of prior periods to conform to the classification used in the current period. The impact of such reclassifications on the consolidated financial statements is not material.

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****3. Business acquisitions****A. Acquisitions*****Pharmalink Consulting Limited and Pharmalink Consulting Inc.***

On May 29, 2014, the Company acquired 100% of the outstanding equity interest in each of Pharmalink Consulting Limited, a company incorporated under the laws of England and Wales, and Pharmalink Consulting Inc., a California corporation (collectively referred to as Pharmalink ). The purchase consideration for the acquisition is set forth below:

Cash consideration after preliminary adjustment for net debt and working capital	\$ 125,901
Fair value of contingent earn-out consideration (ranging from \$0 to \$27,405)	12,730
<b>Total preliminary estimated purchase consideration</b>	<b>\$ 138,631</b>

The contingent earn-out consideration is based on gross profits and order bookings of sustainable outsourcing contracts for the period from June 1, 2014 to June 30, 2016. The total consideration paid at closing for the Company's acquisition of Pharmalink was \$123,701, net of cash acquired of \$2,200. Pharmalink is a provider of regulatory affairs services to the life sciences industry. With this acquisition, the Company adds regulatory consulting, outsourcing and operations capabilities for clients in the life sciences industry.

As of the date of these financial statements, the purchase consideration and the allocation for the acquisition are pending final adjustment for working capital and net debt in accordance with the terms of acquisition agreement. The Company is also evaluating certain tax positions with respect to this acquisition which, when determined, may result in the recognition of additional assets and liabilities as of the acquisition date. Changes to the preliminary recorded assets and liabilities may result in a corresponding adjustment to goodwill. The measurement period will not exceed one year from the acquisition date.

The following table summarizes the preliminary allocation of the preliminary estimated purchase price based on the fair value of the assets acquired and the liabilities assumed as of the date of acquisition:

Preliminary estimated purchase price	\$ 138,631
Acquisition related costs included in selling, general and administrative expenses as incurred	1,977

Recognized amounts of identifiable assets acquired and liabilities assumed	
Net assets acquired (excluding intangible assets and deferred tax asset/(liability), net)	7,174
Intangible assets	29,923
Deferred tax asset/(liability), net	(8,419)
<b>Total identifiable net assets acquired</b>	<b>28,678</b>
Goodwill	\$ 109,953
<b>Total</b>	<b>\$ 138,631</b>

Goodwill has been allocated to the India reporting unit and is not deductible for tax purposes. The intangible assets consist of customer related and marketing related intangible assets with a weighted average amortization period of 6 years.

The results of operations of Pharmalink and the fair value of its assets and liabilities are included in the Company's Consolidated Financial Statements with effect from May 29, 2014, the date of acquisition.

**Table of Contents****GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****4. Cash and cash equivalents**

Cash and cash equivalents as of December 31, 2013 and September 30, 2014 comprise:

	<b>As of December 31, 2013</b>	<b>As of September 30, 2014</b>
Deposits with banks	\$ 123,545	\$ 93,805
Other cash and bank balances	447,731	305,394
<b>Total</b>	<b>\$ 571,276</b>	<b>\$ 399,199</b>

Cash and cash equivalents as of December 31, 2013 and September 30, 2014 include restricted cash balances of \$861 and \$847, respectively. Restrictions primarily consist of margin balances against bank guarantees and deposits for foreign currency advances on which the bank has created a lien.

**5. Accounts receivable, net of reserve for doubtful receivables**

The following table provides details of the reserve for doubtful receivables recorded by the Company:

	<b>As of December 31, 2013</b>	<b>As of September 30, 2014</b>
Opening Balance as of January 1	\$ 9,073	\$ 16,560
Additions due to acquisitions		178
Additions charged to expense	11,420	2,322
Deductions	(3,933)	(3,675)
<b>Closing Balance</b>	<b>\$ 16,560</b>	<b>\$ 15,385</b>

Accounts receivable were \$521,677 and \$549,178, and the reserves for doubtful receivables were \$16,560 and \$15,385, resulting in net accounts receivable balances of \$505,117 and \$533,793, each as of December 31, 2013 and September 30, 2014, respectively. In addition, accounts receivable due after one year of \$15,844 and \$12,388 as of December 31, 2013 and September 30, 2014, respectively, are included under other assets in the Consolidated Balance

Sheets.

Accounts receivable from related parties were \$403 and \$24 as of December 31, 2013 and September 30, 2014, respectively. There are no reserves for doubtful receivables in respect of amounts due from related parties.

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****6. Fair Value Measurements**

The Company measures certain financial assets and liabilities, including derivative instruments, at fair value on a recurring basis. The fair value measurements of these derivative instruments were determined using the following inputs as of December 31, 2013 and September 30, 2014:

**As of December 31, 2013**  
**Fair Value Measurements at Reporting Date Using**  
**Quoted Prices in**  
**Active Markets for Significant Other Significant Other**  
**Identical Observable Unobservable**  
**Assets Inputs Inputs**  
**(Level 1) (Level 2) (Level 3)**

	Total	Identical Assets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)
<b>Assets</b>				
Derivative instruments (Note a)	\$ 7,963	\$	\$ 7,963	\$
<b>Total</b>	<b>\$ 7,963</b>	<b>\$</b>	<b>\$ 7,963</b>	<b>\$</b>
<b>Liabilities</b>				
Derivative instruments (Note b)	\$ 213,941	\$	\$ 213,941	\$
<b>Total</b>	<b>\$ 213,941</b>	<b>\$</b>	<b>\$ 213,941</b>	<b>\$</b>

**As of September 30, 2014**  
**Fair Value Measurements at Reporting Date Using**  
**Quoted Prices in**  
**Active Markets for Significant Other Significant Other**  
**Identical Observable Unobservable**  
**Assets Inputs Inputs**  
**(Level 1) (Level 2) (Level 3)**

	Total	Identical Assets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)
<b>Assets</b>				
Derivative instruments (Note a)	\$ 23,524	\$	\$ 23,524	\$
<b>Total</b>	<b>\$ 23,524</b>	<b>\$</b>	<b>\$ 23,524</b>	<b>\$</b>

Liabilities

Derivative instruments (Note b)	\$ 110,175	\$	\$ 110,175	\$
Total	\$ 110,175	\$	\$ 110,175	\$

- (a) Included in prepaid expenses and other current assets and other assets in the consolidated balance sheets.  
 (b) Included in accrued expenses and other current liabilities and other liabilities in the consolidated balance sheets.  
 The Company values its derivative instruments based on market observable inputs, including both forward and spot prices for the respective currencies. The quotes are taken from an independent market database.

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****7. Derivative financial instruments**

The Company is exposed to the risk of rate fluctuations on foreign currency assets and liabilities and foreign currency denominated forecasted cash flows. The Company has established risk management policies, including the use of derivative financial instruments to hedge foreign currency assets and liabilities and foreign currency denominated forecasted cash flows. These derivative financial instruments are largely deliverable and non-deliverable forward foreign exchange contracts. The Company enters into these contracts with counterparties which are banks or other financial institutions, and the Company considers the risk of non-performance by the counterparties not to be material. The forward foreign exchange contracts mature between zero and sixty-three months and the forecasted transactions are expected to occur during the same period.

The following table presents the aggregate notional principal amounts of outstanding derivative financial instruments together with the related balance sheet exposure:

	Notional principal amounts (note a)		Balance sheet exposure asset (liability) (note b)	
	As of December 31, 2013	As of September 30, 2014	As of December 31, 2013	As of September 30, 2014
Foreign exchange forward contracts denominated in:				
United States Dollars (sell) Indian Rupees (buy)	\$ 1,143,000	\$ 1,275,800	\$ (203,822)	\$ (94,829)
United States Dollars (sell) Mexican Peso (buy)	9,000	8,880	(268)	(189)
United States Dollars (sell) Philippines Peso (buy)	52,200	69,600	(2,357)	(1,341)
Euro (sell) United States Dollars (buy)	43,779	53,479	(2,434)	3,234
Euro (sell) Hungarian Forints (buy)	4,121	955	131	
Euro (sell) Romanian Leu (buy)	61,977	97,874	1,751	1,873
Japanese Yen (sell) Chinese Renminbi (buy)	30,731	41,418	1,970	1,272
Pound Sterling (sell) United States Dollars (buy)	94,338	110,996	(4,312)	(191)
Australian Dollars (sell) United States Dollars (buy)	85,156	107,186	3,363	3,520
			\$ (205,978)	\$ (86,651)

- (a) Notional amounts are key elements of derivative financial instrument agreements but do not represent the amount exchanged by counterparties and do not measure the Company's exposure to credit or market risks. However, the amounts exchanged are based on the notional amounts and other provisions of the underlying derivative financial instrument agreements.
- (b) Balance sheet exposure is denominated in U.S. dollars and denotes the mark-to-market impact of the derivative financial instruments on the reporting date.

FASB guidance on Derivatives and Hedging requires companies to recognize all derivative instruments as either assets or liabilities at fair value in the statement of financial position. In accordance with the FASB guidance on Derivatives and Hedging, the Company designates foreign exchange forward contracts as cash flow hedges for forecasted revenues and the purchase of services. In addition to this program, the Company has derivative instruments that are not accounted for as hedges under the FASB guidance in order to hedge foreign exchange risks related to balance sheet items such as receivables and intercompany borrowings denominated in currencies other than the underlying functional currency.

The fair value of the Company's derivative instruments and their location in the Company's financial statements are summarized in the table below:

	Cash flow hedges		Non-designated	
	As of	As of	As of	As of
	December 31,	September 30,	December 31,	September 30,
	2013	2014	2013	2014
<b>Assets</b>				
Prepaid expenses and other current assets	\$ 6,098	\$ 9,566	\$	\$ 649
Other assets	\$ 1,865	\$ 13,309	\$	\$
<b>Liabilities</b>				
Accrued expenses and other current liabilities	\$ 83,667	\$ 65,790	\$ 26	\$ 769
Other liabilities	\$ 130,248	\$ 43,616	\$	\$

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****7. Derivative financial instruments (Continued)***Cash flow hedges*

For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain (loss) on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same period or periods during which the hedged transaction is recognized in the consolidated statements of income. Gains (losses) on the derivatives, representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, are recognized in earnings as incurred.

In connection with cash flow hedges, the gains (losses) recorded as a component of other comprehensive income (loss), or OCI, and the related tax effects are summarized below:

<b>Three months ended September 30,</b>						<b>Nine months ended September 30,</b>				
<b>2013</b>			<b>2014</b>			<b>2013</b>			<b>2014</b>	
<b>Tax</b>			<b>Tax</b>		<b>Net of</b>	<b>Tax</b>			<b>Tax</b>	
<b>Before-Tax (Expense)</b>	<b>Net of tax</b>	<b>Before-Tax (Expense)</b>	<b>Net of tax</b>	<b>or Benefit</b>	<b>tax</b>	<b>Before-Tax (Expense)</b>	<b>Net of tax</b>	<b>Before-Tax</b>	<b>or</b>	<b>(Expense)</b>
<b>amount</b>	<b>or Benefit</b>	<b>amount</b>	<b>amount</b>	<b>or Benefit</b>	<b>Amount</b>	<b>amount</b>	<b>or Benefit</b>	<b>amount</b>	<b>amount</b>	<b>Benefit</b>
\$ (207,373)	\$ 73,239	\$ (134,134)	\$ (110,016)	\$ 39,256	\$ (70,760)	\$ (163,756)	\$ 59,070	\$ (104,686)	\$ (205,952)	\$ 72,612
(23,185)	8,759	(14,426)	(13,341)	4,809	(8,532)	(44,070)	17,061	(27,009)	(38,395)	13,637
(75,420)	27,031	(48,389)	10,144	(3,919)	6,225	(139,922)	49,502	(90,420)	81,026	(28,447)

(52,235) 18,272 (33,963) 23,485 (8,728) 14,757 (95,852) 32,441 (63,411) 119,421 (42,084)

**\$ (259,608) \$ 91,511 \$ (168,097) \$ (86,531) \$ 30,528 \$ (56,003) \$ (259,608) \$ 91,511 \$ (168,097) \$ (86,531) \$ 30,528**

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****7. Derivative financial instruments (Continued)**

The gains or losses recognized in other comprehensive income (loss) and their effects on financial performance are summarized below:

	Amount of Gain (Loss) recognized in OCI on Derivatives (Effective Portion)		Location of Gain (Loss) reclassified from OCI into Statement of Income (Effective Portion)	Amount of Gain (Loss) reclassified from OCI into Statement of Income (Effective Portion)				Location of Gain (Loss) recognized in Income on Derivatives (Ineffective Portion and Amount excluded from Effective Testing)	Amount of Gain (Loss) recognized in income on Derivatives (Ineffective Portion and Amount excluded from Effectiveness Testing)		
	Nine months ended September 30,			Three months ended September 30,		Nine months ended September 30,			Effective Testing	Three months ended September 30,	Nine months ended September 30,
Derivatives in Cash Hedging Relationships	2013	2014		2013	2014	2013	2014		2013	2014	2013
Forward foreign exchange contracts	\$ (139,922)	\$ 81,026	Revenue	\$ 2,590	\$ (2,089)	\$ 5,957	\$ (4,591)	Foreign exchange losses, net	\$	\$	\$
			Cost of revenue	(20,801)	(8,992)	(40,417)	(26,829)				
			Selling, general and administrative expenses	(4,974)	(2,260)	(9,610)	(6,975)				
	\$ (139,922)	\$ 81,026		\$ (23,185)	\$ (13,341)	\$ (44,070)	\$ (38,395)		\$	\$	\$



Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****7. Derivative financial instruments (Continued)***Non-designated Hedges*

	Location of (Gain) Loss  recognized in Statement of	Amount of (Gain) Loss recognized in Statement of Income on Derivatives			
		Three months ended		Nine months ended	
Derivatives not designated as hedging instruments	Income on Derivatives	September 30, 2013	September 30, 2014	September 30, 2013	September 30, 2014
Forward foreign exchange contracts (Note a)	Foreign exchange (gains) losses, net	\$ 11,359	\$ (197)	\$ 20,944	\$ 66
		<b>\$ 11,359</b>	<b>\$ (197)</b>	<b>\$ 20,944</b>	<b>\$ 66</b>

- (a) These forward foreign exchange contracts were entered into to hedge fluctuations in foreign exchange rates for recognized balance sheet items such as receivables and intercompany borrowings, and were not originally designated as hedges under FASB guidance on derivatives and hedging. Realized (gains) losses and changes in the fair value of these derivatives are recorded in foreign exchange (gains) losses, net in the consolidated statements of income.

**8. Prepaid expenses and other current assets**

Prepaid expenses and other current assets consist of the following:

	<b>As of December 31, 2013</b>	<b>As of September 30, 2014</b>
Advance taxes	\$ 65,053	\$ 116,020
Deferred transition costs	37,050	40,382
Derivative instruments	6,098	10,215
Employee advances	5,397	6,205
Advances to suppliers	1,994	1,192
Prepaid expenses	12,569	15,808
Deposits	3,896	3,031
Others	7,056	10,831
	<b>\$ 139,113</b>	<b>\$ 203,684</b>

### 9. Property, plant and equipment, net

Property, plant and equipment, net consist of the following:

	<b>As of December 31, 2013</b>	<b>As of September 30, 2014</b>
Property, plant and equipment, gross	\$ 502,893	\$ 530,887
Less: Accumulated depreciation and amortization	(329,689)	(354,714)
Property, plant and equipment, net	<b>\$ 173,204</b>	<b>\$ 176,173</b>

Depreciation expense on property, plant and equipment for the nine months ended September 30, 2013 and 2014 was \$35,164 and \$32,701, respectively, and for the three months ended September 30, 2013 and 2014 was \$11,747 and \$11,044, respectively. The amount of computer software amortization for the nine months ended September 30, 2013 and 2014 was \$7,541 and \$6,679, respectively, and for the three months ended September 30, 2013 and 2014 was \$2,438 and \$2,271, respectively.

The depreciation and amortization expense set forth above includes the effect of the reclassification of foreign exchange (gains) losses related to the effective portion of foreign currency derivative contracts, amounting to \$2,435 and \$1,596 for the nine months ended September 30, 2013 and 2014, respectively, and \$1,233 and \$525 for the three months ended September 30, 2013 and 2014, respectively.

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****10. Goodwill and intangible assets**

The following table presents changes in goodwill for the year ended December 31, 2013 and nine months ended September 30, 2014:

	<b>As of December 31, 2013</b>	<b>As of September 30, 2014</b>
Opening balance	\$ 956,064	\$ 953,849
Goodwill relating to acquisitions consummated during the period	37,918	109,953
Goodwill relating to divestitures consummated during the period	(3,450)	
Impact of measurement period adjustments	(362)	
Effect of exchange rate fluctuations	(36,321)	(7,824)
Closing balance	\$ 953,849	\$ 1,055,978

The total amount of goodwill deductible for tax purposes is \$38,512 and \$36,267 as of December 31, 2013 and September 30, 2014, respectively.

The Company's intangible assets acquired either individually or with a group of other assets or in a business combination are as follows:

	<b>As of December 31, 2013</b>			<b>As of September 30, 2014</b>		
	<b>Gross carrying amount</b>	<b>Accumulated amortization</b>	<b>Net</b>	<b>Gross carrying amount</b>	<b>Accumulated amortization</b>	<b>Net</b>
Customer-related intangible assets	\$ 288,983	\$ 213,878	\$ 75,105	\$ 307,586	\$ 225,296	\$ 82,290
Marketing-related intangible assets	37,919	20,545	17,374	43,388	23,093	20,295
Contract-related intangible assets	1,121	1,121		1,125	1,125	
Other intangible assets	9,124	2,487	6,637	16,464	4,124	12,340

\$ 337,147	\$ 238,031	\$ 99,116	\$ 368,563	\$ 253,638	\$ 114,925
------------	------------	-----------	------------	------------	------------

Amortization expenses for intangible assets for the nine months ended September 30, 2013 and 2014 were \$17,603 and \$20,617, respectively, and for the three months ended September 30, 2013 and 2014 were \$5,867 and \$7,989, respectively, and are disclosed in the consolidated statements of income under amortization of acquired intangible assets.

## 11. Short-term borrowings

The Company has the following borrowing facilities:

- (a) Fund-based and non-fund-based credit facilities with banks, which are available for operational requirements in the form of overdrafts, letters of credit, guarantees and short-term loans. As of December 31, 2013 and September 30, 2014, the limits available were \$13,906 and \$14,673, respectively, out of which \$6,689 and \$7,826 was utilized, constituting non-funded drawdown.
- (b) A fund-based and non-fund based revolving credit facility of \$250,000, which was initially entered into in August 2012 and which was amended in June 2013 as described in note 12 below. A portion of this facility was initially used to fund the special cash dividend paid in September 2012 and for the acquisition of Jawood Business Process Solutions, LLC and Felix Software Solutions Private Limited in February 2013. Additionally, this facility was utilized to fund in part the Company's stock purchase and its acquisition of Pharmalink, each in the second quarter of 2014. As of December 31, 2013 and September 30, 2014, a total of \$4,397 and \$167,224, respectively, was utilized, of which \$0 and \$165,000, respectively, constituted funded drawdown and \$4,397 and \$2,224, respectively, constituted non-funded drawdown. This facility expires in August 2017. The funded drawdown amount bears interest at LIBOR plus a margin of 2.50% as of both December 31, 2013 and September 30, 2014. The unutilized amount on the facility bears a commitment fee of 0.50%. Indebtedness under the facility is secured by certain assets of the Company, and the credit agreement contains certain covenants, including a maximum leverage covenant that becomes effective only if the revolving facility is drawn for \$50,000 or more. During the nine months ended September 30, 2014, the Company was in compliance with all of the financial covenants.

**Table of Contents****GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****12. Long-term debt**

In August 2012, the Company obtained credit facilities aggregating \$925,000 from a consortium of financial institutions to (i) finance the repayment of the balance outstanding under its previous credit facility of \$380,000, (ii) fund a portion of its special cash dividend, and (iii) for general corporate purposes of the Company and its subsidiaries, including working capital requirements. The credit facility provides for a term loan of \$675,000 and a revolving credit facility of \$250,000.

In June 2013, the Company amended this credit facility. As a result of the amendment, the applicable margin on the term loan and the revolving credit facility was reduced from 3.25% p.a. to 2.75% p.a. and 2.50% p.a., respectively. In addition, the LIBOR floor on the term loan was reduced from 1% to 0.75%. As of the amendment date, the gross outstanding term loan amounted to \$671,625. The amendment did not result in a substantial modification of \$553,589 of the term loan outstanding prior to the amendment. In connection with the amendment, the Company extinguished \$118,036 of the term loan outstanding as of the amendment date and obtained additional funding amounting to \$121,410, increasing the total term loan outstanding to \$675,000. As a result, the Company expensed \$3,103, which represented a partial acceleration of the amortization of the existing unamortized debt issuance costs and an additional fee paid to the lenders in respect of the extinguished amount. The overall borrowing capacity under the revolving facility did not change. The amendment of the revolving facility resulted in the accelerated amortization of \$54 relating to an existing unamortized debt issuance cost. The remaining unamortized costs and an additional third party fee paid in connection with the amendment of the term loan and revolving facility will be amortized over the term of the term loan and revolving facility, which end on August 30, 2019 and August 30, 2017, respectively.

As of December 31, 2013 and September 30, 2014, the outstanding term loan, net of debt amortization expense of \$13,761 and \$11,898, was \$657,864 and \$654,664, respectively. As of December 31, 2013 and September 30, 2014, the term loan bears interest at LIBOR (LIBOR floor of 0.75%) plus an applicable margin of 2.75% p.a. Indebtedness under the loan facility is secured by certain assets of the Company. The amount outstanding on the term loan as of September 30, 2014 will be repaid through quarterly payments of 0.25% of the principal amount of \$675,000, and the balance will be repaid upon the maturity of the term loan on August 30, 2019.

The maturity profile of the term loan, net of debt amortization expense, is as follows:

<b>Year ended</b>	<b>Amount</b>
2014	\$ 1,063
2015	4,288
2016	4,306
2017	4,338

2018	4,363
2019	636,306
	<b>\$ 654,664</b>

### 13. Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:

	As of December 31, 2013	As of September 30, 2014
Accrued expenses	\$ 98,988	\$ 107,271
Accrued employee cost	126,814	128,975
Deferred transition revenue	46,895	50,225
Statutory liabilities	24,466	19,879
Retirement benefits	14,853	19,537
Derivative instruments	83,693	66,559
Advance from customers	18,334	19,239
Earn-out consideration	3,492	11,252
Other liabilities	4,457	3,595
	\$ 421,992	\$ 426,532

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****14. Employee benefit plans**

The Company has employee benefit plans in the form of certain statutory and other schemes covering its employees.

**Defined benefit plans**

In accordance with Indian law, the Company provides a defined benefit retirement plan (the Gratuity Plan ) covering substantially all of its Indian employees. In accordance with Mexican law, the Company provides termination benefits to all of its Mexican employees. In addition, certain of the Company's subsidiaries in the Philippines and Japan have sponsored defined benefit retirement programs.

Net defined benefit plan costs for the three months and nine months ended September 30, 2013 and 2014 include the following components:

	<b>Three months ended September 30,</b>		<b>Nine months ended September 30,</b>	
	<b>2013</b>	<b>2014</b>	<b>2013</b>	<b>2014</b>
Service costs	\$ 1,528	\$ 1,213	\$ 3,274	\$ 3,629
Interest costs	869	631	1,756	1,888
Amortization of actuarial loss	200	80	650	239
Expected return on plan assets	(298)	(460)	(727)	(1,371)
Net Gratuity Plan costs	\$ 2,299	\$ 1,464	\$ 4,953	\$ 4,385

**Defined contribution plans**

During the three months and nine months ended September 30, 2013 and 2014, the Company contributed the following amounts to defined contribution plans in various jurisdictions:

	<b>Three months ended September 30,</b>		<b>Nine months ended September 30,</b>	
	<b>2013</b>	<b>2014</b>	<b>2013</b>	<b>2014</b>
India	\$ 3,446	\$ 3,883	\$ 10,935	\$ 11,565
U.S.	620	1,415	2,561	4,045
U.K.	405	934	1,352	2,335
Hungary	6		18	4

Edgar Filing: Genpact LTD - Form 10-Q

China	3,899	3,785	10,781	10,703
Mexico	3	3	23	13
Morocco	20		71	2
South Africa	46	58	172	159
Hong Kong	4	5	15	14
Netherlands	345	428	1,427	1,698
Philippines	3	2	11	8
Singapore	2	18	8	42
Japan	611	474	1,577	1,423
Ireland		13		13
<b>Total</b>	<b>9,410</b>	<b>11,018</b>	<b>28,951</b>	<b>32,024</b>

**Table of Contents**

**GENPACT LIMITED AND ITS SUBSIDIARIES**

**Notes to the Consolidated Financial Statements**

**(Unaudited)**

**(In thousands, except per share data and share count)**

**15. Stock-based compensation**

The Company has issued options under the Genpact Global Holdings 2005 Plan (the 2005 Plan ), the Genpact Global Holdings 2006 Plan (the 2006 Plan ), the Genpact Global Holdings 2007 Plan (the 2007 Plan ) and the Genpact Limited 2007 Omnibus Incentive Compensation Plan (the 2007 Omnibus Plan ) to eligible persons who are employees, directors and certain other persons associated with the Company.

With respect to options granted under the 2005, 2006 and 2007 Plans before the date of adoption of the 2007 Omnibus Plan, if an award granted under any of the Plans is forfeited or otherwise expires, terminates, or is cancelled without the delivery of shares, then the shares covered by the forfeited, expired, terminated, or cancelled award will be added to the number of shares otherwise available for grant under the respective Plans.

From the date of adoption of the 2007 Omnibus Plan on July 13, 2007, options forfeited, expired, terminated, or cancelled under any of the plans will be added to the number of shares otherwise available for grant under the 2007 Omnibus Plan. The 2007 Omnibus Plan was amended and restated on April 11, 2012 to increase the number of common shares authorized for issuance by 5,593,200 shares to 15,000,000 shares.

On August 30, 2012, the Company's Board of Directors declared a special cash dividend of \$2.24 per share. The special cash dividend resulted in an adjustment to stock-based awards under both the 2007 Omnibus Plan and the 2005 Plan. Accordingly, effective September 24, 2012, the payment date of the special cash dividend, the number of common shares authorized for issuance under the 2007 Omnibus Plan was increased by 2,544,327 shares. The number of common shares authorized for issuance under the 2005 Plan was increased by 495,915 shares.

Further, as of December 31, 2012, the number of common shares authorized for issuance under the 2007 Omnibus Plan had been increased by 6,314,496 shares as a result of the termination, expiration or forfeiture of options granted under the Company's stock incentive plans other than the 2007 Omnibus Plan. In accordance with the anti-dilutive provisions of the 2005 Plan, 2006 Plan, 2007 Plan and 2007 Omnibus Plan, the Company adjusted both the exercise price and the number of stock-based awards outstanding as of the record date of the special cash dividend. The aggregate fair value, intrinsic value and the ratio of the exercise price to the market price were approximately equal immediately before and after the adjustments. Therefore, in accordance with the equity restructuring guidance under ASC 718, Compensation-Stock Compensation, no incremental compensation expense was recognized for the adjustment to the outstanding stock-based awards as a result of the special cash dividend.

Stock-based compensation costs relating to the foregoing plans during the nine months ended September 30, 2013 and 2014 were \$21,761 and \$19,932, respectively, and for the three months ended September 30, 2013 and 2014 were \$5,258 and \$8,196, respectively. These costs have been allocated to cost of revenue and selling, general, and administrative expenses.

The following table shows the significant assumptions used in connection with the determination of the fair value of options granted in the nine months ended September 30, 2013 and 2014.

	<b>Nine months ended September 30, 2013</b>	<b>Nine months ended September 30, 2014</b>
Dividend Yield	0%	0%
Expected life (in months)	84	84
Risk-free rate of interest	1.55%	2.18% - 2.29%
Volatility	39.39%	37.27% - 38.34%

**Table of Contents****GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****15. Stock-based compensation (Continued)**

A summary of stock option activity during the nine months ended September 30, 2014 is set out below:

	<b>Nine months ended September 30, 2014</b>			
	<b>Shares arising out of options</b>	<b>Weighted average exercise price</b>	<b>Weighted average remaining contractual life (years)</b>	<b>Aggregate intrinsic value</b>
Outstanding as of January 1, 2014	11,102,163	\$ 12.40	5.2	
Granted	520,000	17.54		
Forfeited	(250,673)	19.20		
Expired	(27,228)	12.32		
Exercised*	(1,797,119)	5.61		19,254
Outstanding as of September 30, 2014	9,547,143	\$ 13.78	5.1	\$ 35,509
Vested as of September 30, 2014 and expected to vest thereafter (Note a)	9,217,964	\$ 13.51	5.1	\$ 35,508
Vested and Exercisable as of September 30, 2014	5,697,816	\$ 10.14	2.7	\$ 35,229
Weighted average grant date fair value of grants during the period	\$ 17.54			

(a) Options expected to vest reflect an estimated forfeiture rate.

\* Out of this, 1,000,000 options have been net settled upon exercise by issuing 650,925 shares (net of minimum statutory withholding taxes).

As of September 30, 2014, the total remaining unrecognized stock-based compensation cost for options expected to vest amounted to \$21,383, which will be recognized over the weighted average remaining requisite vesting period of 3.5 years.

**Restricted Share Units**

The Company has granted restricted share units, or RSUs, under the 2007 Omnibus Plan. Each RSU represents the right to receive one common share at a future date. The fair value of each RSU is the market price of one common share of the Company on the date of the grant. The RSUs granted to date have graded vesting schedules of six months to four years. The compensation expense is recognized on a straight-line basis over the vesting term.

A summary of RSUs granted during the nine months ended September 30, 2014 is set out below:

	<b>Nine months ended September 30, 2014</b>	
	<b>Number of Restricted Shares</b>	<b>Weighted Average Grant Date Fair Value</b>
	<b>Units</b>	<b>\$</b>
Outstanding as of January 1, 2014	871,772	13.96
Granted	200,121	16.82
Vested*	(140,574)	14.02
Forfeited	(82,785)	13.81
<b>Outstanding as of September 30, 2014</b>	<b>848,534</b>	<b>14.64</b>
Expected to vest (Note a)	791,168	

(a) RSUs expected to vest reflect an estimated forfeiture rate.

\* Vested RSUs were net settled upon vesting by issuing 87,465 shares (net of minimum statutory withholding taxes).

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****15. Stock-based compensation (Continued)**

44,286 RSUs vested as of December 31, 2012, the shares in respect of which became issuable on December 31, 2013. 43,605 shares were issued in January 2014 after withholding shares to the extent of the minimum statutory withholding taxes.

61,057 RSUs vested in the year ended December 31, 2013, the shares in respect of which will be issuable on December 31, 2014 after withholding shares to the extent of the minimum statutory withholding taxes.

As of September 30, 2014, the total remaining unrecognized stock-based compensation cost related to RSUs amounted to \$6,769, which will be recognized over the weighted average remaining requisite vesting period of 1.9 years.

**Performance Units**

The Company has granted stock awards in the form of Performance Units, or PUs, under the 2007 Omnibus Plan. Each PU represents the right to receive one common share at a future date based on the Company's performance against specified targets. PUs granted to date have vesting schedules of six months to three years. The fair value of each PU is the market price of one common share of the Company on the date of grant, and assumes that performance targets will be achieved. The PUs granted under the plan are subject to cliff or graded vesting. For awards with cliff vesting, the compensation expense is recognized on a straight-line basis over the vesting terms, and for awards with graded vesting, the compensation expense is recognized over the vesting term of each separately vesting portion. Over the performance period, the number of shares to be issued is adjusted upward or downward based upon the probability of achievement of the performance targets. The ultimate number of shares issued and the related compensation cost recognized as an expense will be based on a comparison of the final performance metrics to the specified targets.

A summary of PU activity during the nine months ended September 30, 2014 is set out below:

	<b>Nine months ended September 30, 2014</b>		
		<b>Weighted Average</b>	
	<b>Number of Performance</b>	<b>Grant Date Fair</b>	<b>Maximum Shares</b>
	<b>Units</b>	<b>Value</b>	<b>Eligible to Receive</b>
Outstanding as of January 1, 2014	3,913,733	\$ 16.44	6,149,018
Granted	1,337,750	16.78	2,729,125

Edgar Filing: Genpact LTD - Form 10-Q

Vested*	(139,930)	12.04	(139,930)
Forfeited**	(2,616,122)	17.64	(2,647,022)
Addition due to achievement of higher than target performance goals*	139,930	12.04	
Reduction due to achievement of lower than maximum performance goals***			(2,095,354)
Outstanding as of September 30, 2014	2,635,360	\$ 15.42	3,995,836
Expected to vest (Note a)	2,634,843		

**Table of Contents**

**GENPACT LIMITED AND ITS SUBSIDIARIES**

**Notes to the Consolidated Financial Statements**

**(Unaudited)**

**(In thousands, except per share data and share count)**

**15. Stock-based compensation (Continued)**

(a) PUs expected to vest are based on the probable achievement of performance targets after considering an estimated forfeiture rate.

\* Represents an additional 122,490 and 17,440 shares issued for the PUs granted in March 2011 and June 2011, respectively, as a result of achievement of higher than target performance as certified by the compensation committee based on the Company's audited financial statements.

697,853 and 432 shares, including the additional shares achieved, were issued in March 2014 and April 2014 with respect to grants made in March 2011, and 77,619 shares, including the additional shares achieved, were issued in March 2014 with respect to grants made in June 2011, after withholding shares to the extent of the minimum statutory withholding taxes.

\*\* Includes 251,427 shares underlying PUs granted in May 2011, 1,244,507 shares underlying PUs granted in March 2013 and 630,000 shares underlying PUs granted in May 2013, all of which were forfeited due to non-fulfillment of the performance conditions as certified by the compensation committee based on the Company's audited financial statements.

\*\*\* Represents a reduction of 333,002 and 39,285 of the maximum shares eligible to vest with respect to PUs granted in March 2011 and June 2011, respectively, as a result of the compensation committee's certification of the level of achievement of the performance conditions based on the Company's audited financial statements. Also includes a reduction of 616,568 shares for grants made in March 2013, 985,500 shares for grants made in May 2013 and 121,000 shares for grants made in May 2011, due to non-fulfillment of the performance conditions as certified by the compensation committee based on the Company's audited financial statements.

For the PUs granted in August 2010, vesting for the year ended December 31, 2012 took place at 122.2% of the target shares, or 231,029 shares, based on the compensation committee's certification of achievement of the performance goals for the performance period based on the Company's audited consolidated financial statements. 138,035 shares underlying such PUs were issued in January 2014 after withholding shares to the extent of the minimum statutory withholding taxes.

As of September 30, 2014, the total remaining unrecognized stock-based compensation cost related to PUs amounted to \$20,055, which will be recognized over the weighted average remaining requisite vesting period of 2.1 years.

Prior to the 2012 Recapitalization, under the 2007 Omnibus Plan, the definition of change of control included the acquisition by any person, corporation or other entity or group other than GA, OH, GE or any of their affiliates of 25% or more of the voting securities of the Company. The purchase by Bain Capital of Company shares from GA and

OH would have constituted a change of control under the 2007 Omnibus Plan resulting in (1) accelerated vesting of the PUs granted in August 2010 to the former CEO (who since assumed the role of Non-Executive Vice-Chairman) and the PUs granted to the Company's Chief Executive Officer in June 2011 and March 2012, (2) double-trigger vesting of the outstanding PUs granted in March 2010 and March 2011 based on an abbreviated performance period ending with the close of the Company's fiscal quarter coincident with or immediately preceding the effective date of the Change of Control in the event of a termination without cause in the twenty-four months following a change of control and (3) double-trigger vesting of the outstanding PUs granted in March 2012 based on target performance in the event of a termination without cause in the twenty-four months following a change of control. Because the Board of Directors determined that Bain Capital's purchase of Company shares from GA and OH was not the type of transaction intended to constitute a change of control under the 2007 Omnibus Plan, it amended the 2007 Omnibus Plan to provide that the contemplated transaction among Bain Capital, GA and OH would not constitute a change of control thereunder. In addition, the CEO and Non-Executive Vice-Chairman waived any accelerated vesting of their PUs, and all affected employees consented to the amendment of the change of control definition. As a result of the foregoing, all such PUs will continue to vest in accordance with their original terms.

The amendment to the 2007 Omnibus Plan constituted a modification to the PUs effective as of October 25, 2012, as a result of which 123 employees were affected and an incremental compensation cost of \$5,500 was determined and will be recognized over a weighted average period of 1.85 years. The incremental compensation cost due to this modification was a result of considering the original performance period in determining expected vesting as against the abbreviated performance period for 2010 and 2011 PU grants and vesting at target for 2012 PU grants.

**Table of Contents**

**GENPACT LIMITED AND ITS SUBSIDIARIES**

**Notes to the Consolidated Financial Statements**

**(Unaudited)**

**(In thousands, except per share data and share count)**

**15. Stock-based compensation (Continued)**

**Employee Stock Purchase Plan (ESPP)**

On May 1, 2008, the Company adopted the Genpact Limited U.S. Employee Stock Purchase Plan and the Genpact Limited International Employee Stock Purchase Plan (together, the ESPP ).

The ESPP allows eligible employees to purchase the Company's common shares through payroll deduction at 90% of the fair value of a Company common share on the last business day of each purchase interval. The dollar amount of common shares purchased under the ESPP must not exceed 15% of the participating employee's base salary, subject to a cap of \$25 per employee per calendar year. With effect from September 1, 2009, the offering periods commence on the first business day in March, June, September and December of each year and end on the last business day in the subsequent May, August, November and February of each year. 4,200,000 common shares have been reserved for issuance in the aggregate over the term of the ESPP.

During the nine months ended September 30, 2013 and 2014, the Company issued 81,040 and 117,305 common shares, respectively, under the ESPP.

The ESPP is considered compensatory under the FASB guidance on Compensation-Stock Compensation.

The compensation expense for the employee stock purchase plan is recognized in accordance with the FASB guidance on Compensation-Stock Compensation. The compensation expense for the ESPP during the nine months ended September 30, 2013 and 2014 was \$170 and \$221, respectively, and for the three months ended September 30, 2013 and 2014 was \$54 and \$77, respectively, and has been allocated to cost of revenue and selling, general, and administrative expenses.

**16. Capital Stock**

***Stock Purchase***

On April 8, 2014, the Company purchased 17,292,842 of its common shares at \$17.50 per share for an aggregate cash amount of approximately \$302,625 pursuant to the Company's modified Dutch Auction self-tender offer announced on March 5, 2014. Under the terms of the offer the Company was authorized to purchase up to \$300,000 of its common shares. The number of shares accepted for purchase included the Company's exercise of its right to upsize the offer by up to 2% of the Company's shares then outstanding. The purchased shares have been retired.

Any purchase by the Company of its common shares is accounted for when the transaction is settled. There were no unsettled share purchases as of September 30, 2014. Shares purchased and retired are deducted to the extent of their par value from common stock and from retained earnings for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares. For the nine months ended September 30, 2013 and 2014, \$0 and \$2,543, respectively, were deducted from retained earnings as direct costs related to share purchases.

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****17. Earnings per share**

The Company calculates earnings per share in accordance with FASB guidance on Earnings per Share. Basic and diluted earnings per common share give effect to the change in the number of common shares of the Company outstanding. The calculation of basic earnings per common share was determined by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the respective periods. The potentially dilutive shares, consisting of outstanding options on common shares, restricted share units, performance units and common shares to be issued under the ESPP have been included in the computation of diluted net earnings per share and the weighted average number of shares outstanding, except where the result would be anti-dilutive.

The number of stock awards outstanding but not included in the computation of diluted earnings per common share because their effect was anti-dilutive is 2,327,000 and 3,467,390 for the nine months ended September 30, 2013 and 2014, respectively, and 3,483,000 and 3,567,728 for the three months ended September 30, 2013 and 2014, respectively.

	<b>Three months ended September 30,</b>		<b>Nine months ended September 30,</b>	
	<b>2013</b>	<b>2014</b>	<b>2013</b>	<b>2014</b>
<b>Net income available to Genpact Limited common shareholders</b>	\$ 70,262	\$ 46,653	\$ 180,875	\$ 146,250
Weighted average number of common shares used in computing basic earnings per common share	230,057,508	216,472,908	228,840,746	222,036,262
Dilutive effect of stock-based awards	6,279,416	4,062,622	6,254,914	4,404,088
Weighted average number of common shares used in computing dilutive earnings per common share	236,336,924	220,535,530	235,095,660	226,440,350
<b>Earnings per common share attributable to Genpact Limited common shareholders</b>				
Basic	\$ 0.31	\$ 0.22	\$ 0.79	\$ 0.66
Diluted	\$ 0.30	\$ 0.21	\$ 0.77	\$ 0.65

**18. Cost of revenue**

Cost of revenue consists of the following:

	<b>Three months ended September 30,</b>		<b>Nine months ended September 30,</b>	
	<b>2013</b>	<b>2014</b>	<b>2013</b>	<b>2014</b>
Personnel expenses	\$ 223,976	\$ 244,466	\$ 671,518	\$ 701,469
Operational expenses	93,235	98,841	265,894	284,329
Depreciation and amortization	12,078	11,168	36,317	33,091
	\$ 329,289	\$ 354,475	\$ 973,729	\$ 1,018,889

**19. Selling, general and administrative expenses**

Selling, general and administrative expenses consist of the following:

	<b>Three months ended September 30,</b>		<b>Nine months ended September 30,</b>	
	<b>2013</b>	<b>2014</b>	<b>2013</b>	<b>2014</b>
Personnel expenses	\$ 83,580	\$ 111,427	\$ 251,379	\$ 302,115
Operational expenses	31,318	39,574	90,865	109,957
Depreciation and amortization	2,107	2,147	6,388	6,289
	\$ 117,005	\$ 153,148	\$ 348,632	\$ 418,361

Table of Contents**GENPACT LIMITED AND ITS SUBSIDIARIES****Notes to the Consolidated Financial Statements****(Unaudited)****(In thousands, except per share data and share count)****20. Other operating (income) expense, net**

	Three months ended September 30,		Nine months ended September 30,	
	2013	2014	2013	2014
Other operating (income) expense	\$ (1,051)	\$ (372)	\$ (2,260)	\$ (926)
Provision for impairment of capital work in progress / property, plant and equipment			2,392	
Change in fair value of earn out consideration and deferred consideration (relating to business acquisitions)	(2,181)		(4,452)	(2,198)
<b>Other operating (income) expense, net</b>	<b>\$ (3,232)</b>	<b>\$ (372)</b>	<b>\$ (4,320)</b>	<b>\$ (3,124)</b>

**21. Other income (expense), net**

Other income (expense), net consists of the following:

	Three months ended September 30,		Nine months ended September 30,	
	2013	2014	2013	2014
Interest income	\$ 4,355	\$ 1,597	\$ 14,114	\$ 3,582
Interest expense*	(8,134)	(8,986)	(30,861)	(24,395)
Provision (created) reversed for loss on divestures	141		(3,520)	
Other income (expense)	184	950	1,163	1,336
<b>Other income (expense), net</b>	<b>\$ (3,454)</b>	<b>\$ (6,439)</b>	<b>\$ (19,104)</b>	<b>\$ (19,477)</b>

\* The three months and nine months ended September 30, 2013 include \$0 and \$3,157, respectively, representing partial acceleration of the amortization of debt issuance costs and an additional fee paid to the Company's lenders in connection with the amendment of the credit facility as described in Note 12.

**22. Income taxes**

The Company determines the tax provision for interim periods using an estimate of its annual effective tax rate adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if its estimated tax rate changes, the Company makes a cumulative adjustment.

As of December 31, 2013, the Company had unrecognized tax benefits amounting to \$21,832, including an amount of \$20,901 that, if recognized, would impact the effective tax rate.

The following table summarizes the activities related to the Company's unrecognized tax benefits for uncertain tax positions from January 1, 2014 to September 30, 2014:

Opening Balance at January 1	\$ 21,832
Increase related to prior year tax positions, including recorded in acquisition accounting	1,273
Decrease related to prior year tax positions	(862)
Effect of exchange rate changes	7
Closing Balance at September 30	\$ 22,250

The Company's unrecognized tax benefits as of September 30, 2014 include an amount of \$21,332 that, if recognized, would impact the effective tax rate. As of December 31, 2013 and September 30, 2014, the Company has accrued approximately \$3,373 and \$3,373, respectively, in interest relating to unrecognized tax benefits. During the year ended December 31, 2013 and nine months ended September 30, 2014, the company recognized approximately \$(50) and \$9, respectively, in interest expense. As of December 31, 2013 and September 30, 2014, the Company has accrued approximately \$350 and \$564, respectively, for penalties.

**Table of Contents**

**GENPACT LIMITED AND ITS SUBSIDIARIES**

**Notes to the Consolidated Financial Statements**

**(Unaudited)**

**(In thousands, except per share data and share count)**

**23. Related party transactions**

The Company has entered into related party transactions with its non-consolidating affiliates. During the year ended December 31, 2013, the Company acquired the remaining equity interest in one of its non-consolidating affiliates, which is now a wholly-owned subsidiary. The Company has also entered into related party transactions with a significant shareholder and its affiliates.

The Company's related party transactions can be categorized as follows:

*Revenue from services*

For the nine months ended September 30, 2013 and 2014, the Company recognized net revenues of \$571 and \$0, respectively, and for the three months ended September 30, 2013 and 2014, the Company recognized net revenues of \$190 and \$0, respectively, from a client who is an affiliate of a significant shareholder of the Company.

For the nine months ended September 30, 2013 and 2014, the Company recognized net revenues of \$0 and \$214, respectively, and for the three months ended September 30, 2013 and 2014, the Company recognized net revenues of \$0 and \$72, respectively, from a client who is a significant shareholder of the Company.

*Cost of revenue from services*

The Company purchases certain services from its non-consolidating affiliates mainly relating to training and recruitment, which are included in cost of revenue. For the nine months ended September 30, 2013 and 2014, cost of revenue includes an amount of \$1,527 and \$1,635, respectively, and for the three months ended September 30, 2013 and 2014, cost of revenue includes an amount of \$563 and \$662, respectively, attributable to the cost of services from the Company's non-consolidating affiliates.

*Selling, general and administrative expenses*

The Company purchases certain services from its non-consolidating affiliates mainly relating to training and recruitment, which are included in selling, general and administrative expenses. For the nine months ended September 30, 2013 and 2014, selling, general and administrative expenses includes an amount of \$356 and \$482, respectively, and for the three months ended September 30, 2013 and 2014, selling, general and administrative expenses includes an amount of \$135 and \$179, respectively, attributable to the cost of services from the Company's non-consolidating affiliates.

**24. Commitments and contingencies**

*Capital commitments*

As of December 31, 2013 and September 30, 2014, the Company has committed to spend \$4,491 and \$5,880, respectively, under agreements to purchase property, plant and equipment. These amounts are net of capital advances paid in respect of such purchases.

*Bank guarantees*

The Company has outstanding bank guarantees amounting to \$11,086 and \$10,050 as of December 31, 2013 and September 30, 2014, respectively. Bank guarantees are generally provided to government agencies and excise and customs authorities for the purposes of maintaining a bonded warehouse. These guarantees may be revoked by the government agencies if they suffer any losses or damage through the breach of any of the covenants contained in the agreements governing such guarantees.

*Other commitments*

The Company's business process delivery centers in India are 100% export oriented units or Software Technology Parks of India units ( STPI ) under the STPI guidelines issued by the Government of India. These units are exempt from customs, central excise duties and levies on imported and indigenous capital goods, stores and spares. The Company has undertaken to pay custom duties, service taxes, levies and liquidated damages payable, if any, in respect of imported and indigenous capital goods, stores and spares consumed duty free in the event that certain terms and conditions are not fulfilled.

---

**Table of Contents**

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion should be read in conjunction with our consolidated financial statements and the related notes that appear elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2013 and with the information under the heading Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2013. In addition to historical information, this discussion includes forward-looking statements and information that involve risks, uncertainties and assumptions, including but not limited to those listed below and under Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 and in our Annual Report on Form 10-K for the year ended December 31, 2013.*

**Special Note Regarding Forward-Looking Statements**

We have made statements in this Quarterly Report on Form 10-Q (the Quarterly Report) in, among other sections, this Part I, Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations that are forward-looking statements. In some cases, you can identify these statements by forward-looking terms such as expect, anticipate, intend, plan, believe, seek, estimate, could, may, shall, will, would and v and similar expressions, or the negative of such words or similar expressions. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, which in some cases may be based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks outlined in Part II, Item 1A Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 and in Part I, Item 1A Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2013. These forward looking statements include, but are not limited to, statements relating to:

our ability to retain existing clients and contracts;

our ability to win new clients and engagements;

the expected value of the statements of work under our master service agreements;

our beliefs about future trends in our market;

political, economic or business conditions in countries where we have operations or where our clients operate;

expected spending on business process outsourcing and information technology services by clients;

foreign currency exchange rates;

our rate of employee attrition;

our effective tax rate; and

competition in our industry.

Factors that may cause actual results to differ from expected results include, among others:

our ability to grow our business and effectively manage growth and international operations while maintaining effective internal controls;

our dependence on revenues derived from clients in the United States and Europe;

our ability to hire and retain enough qualified employees to support our operations;

our dependence on favorable tax legislation and tax policies that may be amended in a manner adverse to us or be unavailable to us in the future;

our ability to maintain pricing and asset utilization rates;

our ability to successfully consummate or integrate strategic acquisitions;

increases in wages in locations in which we have operations;

our relative dependence on the General Electric Company (GE);

financing terms, including, but not limited to, changes in the London Interbank Offered Rate, or LIBOR;

restrictions on visas for our employees traveling to North America and Europe;

**Table of Contents**

fluctuations in exchange rates between the U.S. dollar, the euro, U.K. pound sterling, Chinese renminbi, Hungarian forint, Japanese yen, Indian rupee, Australian dollar, Philippines peso, Guatemalan quetzal, Mexican peso, Moroccan dirham, Polish zloty, Romanian leu, South African rand, Hong Kong dollar, Singapore dollar, United Arab Emirates dirham, Brazilian real, Swiss franc, Swedish krona, Danish krone, Kenyan shilling, Czech koruna, Canadian dollar, Colombian peso, Peruvian nuevo, Taiwan dollar, Saudi Arabian riyal, Indonesian rupiah and Thai bhat;

our ability to retain senior management;

the selling cycle for our client relationships;

our ability to attract and retain clients and our ability to develop and maintain client relationships on attractive terms;

legislation in the United States or elsewhere that adversely affects the performance of business process outsourcing and information technology services offshore;

increasing competition in our industry;

telecommunications or technology disruptions or breaches, or natural or other disasters;

our ability to protect our intellectual property and the intellectual property of others;

further deterioration in the global economic environment and its impact on our clients, including the bankruptcy of our clients;

regulatory, legislative and judicial developments, including the withdrawal of governmental fiscal incentives;

the international nature of our business;

technological innovation;

our ability to derive revenues from new service offerings; and

unionization of any of our employees.

Although we believe the expectations reflected in the forward-looking statements are reasonable at the time they are made, we cannot guarantee future results, level of activity, performance or achievements. Achievement of future results is subject to risks, uncertainties, and potentially inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements. We undertake no obligation to update any of these forward-looking statements after the date of this filing to conform our prior statements to actual results or revised expectations. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-K, Form 10-Q and Form 8-K reports to the SEC.

## Overview

Genpact stands for generating business impact. We design, transform, and run intelligent business operations, including those that are complex and specific to a set of chosen industries. The result is advanced operating models that foster growth and manage cost, risk, and compliance across a range of functions such as finance and procurement, financial services account servicing, claims management, regulatory affairs, and industrial asset optimization. Our Smart Enterprise Processes (SEP<sup>SM</sup>) proprietary framework integrates effective technology and data-driven insight into the fabric of enterprise processes to help our clients be more competitive. Our hundreds of long-term clients include more than one-fourth of the Fortune Global 500. We have grown to over 67,500 people in 25 countries with key management and corporate offices in New York City. Our clients attribute much of our success to our unique history behind our passion for process and operational excellence is the Lean and Six Sigma heritage of a former General Electric division that has served GE businesses for more than 16 years.

In the quarter ended September 30, 2014, we had net revenues of \$588.1 million, of which \$470.8 million, or 80.1%, was from clients other than GE, which we refer to as Global Clients, with the remaining \$117.3 million, or 19.9%, from GE.

In the 12 months ending September 30, 2014, Genpact grew client relationships with annual revenues over \$5 million to 88 from 77 as of September 30, 2013. This includes client relationships with more than \$15 million in annual revenue increasing to 30 from 25, and client relationships with more than \$25 million in annual revenue increasing to 15 from 12.

Our registered office is located at Canon's Court, 22 Victoria Street, Hamilton HM 12, Bermuda.

**Table of Contents****Acquisitions**

In May 2014, we acquired 100% of the outstanding equity interest in each of Pharmalink Consulting Limited and Pharmalink Consulting Inc. (collectively referred to as Pharmalink ), providers of regulatory affairs services to the life sciences industry, for cash consideration of \$125.9 million, subject to adjustment for net debt and working capital. The acquisition agreement also provides for contingent earn-out consideration (ranging from \$0 to \$27.4 million) which had an estimated fair value of \$12.7 million as of the acquisition date. This acquisition gives us regulatory consulting, outsourcing and operations capabilities for our clients in the life sciences industry. Goodwill of \$110.0 million, representing the excess of the preliminary estimated purchase price over the net assets acquired, has been allocated to our India reporting unit.

**Critical Accounting Policies and Estimates**

For a description of our critical accounting policies, see Note 2 Summary of significant accounting policies under Part I, Item 1 Financial Statements above, Part II, Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations Critical Accounting Policies and Estimates, and Note 2 Summary of significant accounting policies under Part IV, Item 15 Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2013.

**Results of Operations**

The following table sets forth certain data from our consolidated statements of income for the three months and nine months ended September 30, 2013 and 2014.

	Three months ended		Nine months ended		Percentage Change Increase/(Decrease)	
	September 30,		September 30,		Three	Nine
					months	months
					ended	ended
	September 30,		September 30,		September 30,	September 30,
	2013		2013		2014	2014 vs.
	2014		2014		2013	2013
	(dollars in millions)		(dollars in millions)		vs.	2013
Net revenues GE*	\$ 118.0	\$ 117.3	\$ 356.7	\$ 347.2	(0.6)%	(2.6)%
Net revenues Global Clients*	416.9	470.8	1,216.9	1,330.7	12.9%	9.3%
<b>Total net revenues</b>	<b>534.9</b>	<b>588.1</b>	<b>1,573.5</b>	<b>1,677.9</b>	<b>9.9%</b>	<b>6.6%</b>
Cost of revenue	329.3	354.5	973.7	1,018.9	7.6%	4.6%
<b>Gross profit</b>	<b>205.6</b>	<b>233.6</b>	<b>599.8</b>	<b>659.0</b>	<b>13.6%</b>	<b>9.9%</b>
<b>Gross profit margin</b>	<b>38.4%</b>	<b>39.7%</b>	<b>38.1%</b>	<b>39.3%</b>		
Operating expenses:						

Edgar Filing: Genpact LTD - Form 10-Q

Selling, general and administrative expenses	117.0	153.1	348.6	418.4	30.9%	20.0%
Amortization of acquired intangible assets	5.9	8.0	17.6	20.6	36.2%	17.1%
Other operating (income) expense, net	(3.2)	(0.4)	(4.3)	(3.1)	(88.5)%	(27.7)%
<b>Income from operations</b>	<b>86.0</b>	<b>72.9</b>	<b>237.9</b>	<b>223.2</b>	<b>(15.2)%</b>	<b>(6.2)%</b>
<b>Income from operations as a percentage of total net revenues</b>	<b>16.1%</b>	<b>12.4%</b>	<b>15.1%</b>	<b>13.3%</b>		
Foreign exchange (gains) losses, net	(10.8)	4.7	(24.6)	12.1	(143.2)%	(149.1)%
Other income (expense), net	(3.5)	(6.4)	(19.1)	(19.5)	86.4%	2.0%
<b>Income before equity method investment activity, net and income tax expense</b>	<b>93.3</b>	<b>61.8</b>	<b>243.4</b>	<b>191.6</b>	<b>(33.8)%</b>	<b>(21.3)%</b>
Equity method investment activity, net	(0.0)	(0.0)	(0.1)	(0.1)		(37.4)%
<b>Income before income tax expense</b>	<b>93.4</b>	<b>61.8</b>	<b>243.5</b>	<b>191.7</b>	<b>(33.8)%</b>	<b>(21.3)%</b>
Income tax expense	21.9	15.1	58.4	45.3	(31.0)%	(22.5)%
<b>Net income</b>	<b>71.4</b>	<b>46.7</b>	<b>185.1</b>	<b>146.4</b>	<b>(34.7)%</b>	<b>(20.9)%</b>
Net income attributable to noncontrolling interest	1.2	0.0	4.3	0.2	(98.9)%	(96.0)%
<b>Net income attributable to Genpact Limited shareholders</b>	<b>\$ 70.3</b>	<b>\$ 46.7</b>	<b>\$ 180.9</b>	<b>\$ 146.3</b>	<b>(33.6)%</b>	<b>(19.1)%</b>
<b>Net income attributable to Genpact Limited shareholders as a percentage of total net revenues</b>	<b>13.1%</b>	<b>7.9%</b>	<b>11.5%</b>	<b>8.7%</b>		

\* Net revenues from certain businesses in which GE ceased to be a 20% shareholder are classified as a part of GE net revenues up to the time of their divestiture by GE and as a part of Global Client net revenues post-divestiture. Net revenues from GE in the third quarter of 2014, after excluding net revenues from such dispositions by GE, decreased by 0.4% from the third quarter of 2013. Net revenues from GE in the nine months ended September 30, 2014, after excluding net revenues from such dispositions by GE, decreased by 1.5% from the nine months ended September 30, 2013.

**Table of Contents****Three Months Ended September 30, 2014 Compared to the Three Months Ended September 30, 2013**

*Net revenues.* Our net revenues were \$588.1 million in the third quarter of 2014, up \$53.2 million, or 9.9%, from \$534.9 million in the third quarter of 2013. The growth in net revenues was primarily driven by an increase in business process outsourcing, or BPO, services delivered to our Global Clients, an increase in information technology, or IT, services delivered to both our Global Clients and GE, and by the acquisition of Pharmalink, which we refer to as our regulatory affairs acquisition. Our annualized net revenue per employee for the third quarter of 2014 was \$36,200, unchanged from the third quarter of 2013. Our average headcount increased to approximately 65,000 in the third quarter of 2014 from approximately 59,200 in the third quarter of 2013.

	Three months ended September 30, Increase/(Decrease)		Percentage Change
	2013	2014	2014 vs. 2013
	(dollars in millions)		
BPO Services	\$ 401.7	\$ 446.8	11.2%
IT Services	133.2	141.3	6.1
<b>Total net revenues</b>	<b>\$ 534.9</b>	<b>\$ 588.1</b>	<b>9.9%</b>

Net revenues from BPO services for the third quarter of 2014 were \$446.8 million, up \$45.1 million, or 11.2%, from \$401.7 million in the third quarter of 2013. This increase was primarily attributable to an increase in revenues from our Global Clients, particularly for finance and accounting services, consulting services and core vertical operations, and to our regulatory affairs acquisition. Net revenues from IT services were \$141.3 million in the third quarter of 2014, up \$8.1 million, or 6.1%, from \$133.2 million in the third quarter of 2013 due to an increase in IT services delivered to both our Global Clients and GE.

Net revenues from BPO services as a percentage of total net revenues increased to 76.0% in the third quarter of 2014 from 75.1% in the third quarter of 2013 with a corresponding decline in the percentage of total net revenues attributable to IT services.

	Three months ended September 30, Increase/(Decrease)		Percentage Change
	2013	2014	2014 vs. 2013
	(dollars in millions)		
Global Clients	\$ 416.9	\$ 470.8	12.9%
GE	118.0	117.3	(0.6)
<b>Total net revenues</b>	<b>\$ 534.9</b>	<b>\$ 588.1</b>	<b>9.9%</b>

Net revenues from Global Clients in the third quarter of 2014 were \$470.8 million, up \$54.0 million, or 12.9%, from \$416.9 million in the third quarter of 2013. This increase was primarily driven by growth in four of our targeted verticals – namely, life sciences, consumer product goods, insurance, and infrastructure, manufacturing and services including revenues derived from our regulatory affairs acquisition. BPO and IT services revenues from Global Clients grew by 15.9% and 4.3%, respectively.



**Table of Contents**

Net revenues from GE were \$117.3 million in the third quarter of 2014, down \$0.7 million, or 0.6%, from the third quarter of 2013 primarily as a result of an expected decline in BPO services, which was partially offset by growth in short cycle IT and consulting projects. Net revenues from GE as a percentage of our total net revenues declined from 22.1% in the third quarter of 2013 to 19.9% in the third quarter of 2014.

Net revenues by geographic region based on the location of our service delivery centers are as follows:

	Three months ended September 30,		Percentage change
	2013	2014	2014 vs. 2013
	(dollars in millions)		
India	\$ 353.1	\$ 392.3	11.1%
Americas	73.3	78.8	7.4
Asia, other than India	55.4	57.8	4.4
Europe	53.1	59.2	11.4
<b>Total net revenues</b>	<b>\$ 534.9</b>	<b>\$ 588.1</b>	<b>9.9%</b>

Net revenues grew in all of our geographic regions in the third quarter of 2014. Net revenues from service delivery centers located in Europe grew the most, contributing \$59.2 million to total net revenues in the third quarter of 2014, up \$6.1 million, or 11.4%, from the third quarter of 2013. Approximately \$4.3 million of this increase was attributable to our regulatory affairs acquisition. Net revenues attributable to India-based service delivery centers were \$392.3 million in the third quarter of 2014, up 11.1% from the third quarter of 2013. A portion of net revenues attributable to India-based service delivery centers includes net revenues for services performed from service delivery centers outside India that are managed by India-based service delivery leaders or at clients' premises outside India by personnel normally based in India. Net revenues from service delivery centers located in the Americas contributed \$78.8 million to total net revenues in the third quarter of 2014, up \$5.5 million, or 7.4%, from the third quarter of 2013 primarily due to revenues derived from our regulatory affairs acquisition. The balance of net revenues, which is attributable to service delivery centers located in Asia, other than India primarily China and the Philippines was \$57.8 million in the third quarter of 2014, up 4.4% from the third quarter of 2013.

*Cost of revenue and gross profit.* The following table sets forth the components of our cost of revenue and the resulting gross profit:

	Three months ended September 30,		as a percentage of total net revenues	
	2013	2014	2013	2014
	(dollars in millions)			
Personnel expenses	\$ 224.0	\$ 244.5	41.9%	41.6%
Operational expenses	93.2	98.8	17.4	16.8
Depreciation and amortization	12.1	11.2	2.3	1.9
<b>Cost of revenue</b>	<b>\$ 329.3</b>	<b>\$ 354.5</b>	<b>61.6%</b>	<b>60.3%</b>
<b>Gross profit</b>	<b>\$ 205.6</b>	<b>\$ 233.6</b>	<b>38.4%</b>	<b>39.7%</b>

Our gross margin increased from 38.4% in the third quarter of 2013 to 39.7% in the third quarter of 2014. This increase is primarily attributable to improved operational efficiencies, including more effective deployment and use of operations personnel. The increase in gross margin is also attributable to foreign exchange volatility, which causes gains and losses on our foreign currency hedges and has a foreign currency translation impact when we convert our non-U.S. dollar revenues to the U.S. dollar, our reporting currency. The impact of these factors was partially offset by the effects of wage inflation.

Cost of revenue in the third quarter of 2014 was \$354.5 million, up \$25.2 million, or 7.6%, from the third quarter of 2013. Of this increase, approximately \$7.8 million, or 31.0%, is attributable to our regulatory affairs acquisition. Wage inflation and an increase in personnel expenses due to an increase in our operational headcount also contributed to higher cost of revenue in the third quarter of 2014 compared to the third quarter of 2013. These increases were partially offset by the operational efficiencies described above and by the effects of foreign exchange volatility. As a result, cost of revenue as a percentage of total net revenues decreased from 61.6% in the third quarter of 2013 to 60.3% in the third quarter of 2014.

**Table of Contents**

*Personnel expenses.* Personnel expenses in the third quarter of 2014 were \$244.5 million, up \$20.5 million, or 9.1%, from \$224.0 million in the third quarter of 2013. This increase was primarily the result of wage inflation, an increase in our operational headcount, and additional personnel expenses resulting from our regulatory affairs acquisition. As a percentage of total net revenues, personnel expenses decreased from 41.9% in the third quarter of 2013 to 41.6% in the third quarter of 2014. This decrease was primarily due to improved operational efficiencies, including more effective deployment and use of operations personnel, and the effects of foreign exchange volatility.

*Operational expenses.* Operational expenses for the third quarter of 2014 were \$98.8 million, up \$5.6 million, or 6.0%, from the third quarter of 2013. This increase was the result of the increased use of subcontractors and an approximately \$3.8 million increase in operational expenses attributable to our regulatory affairs acquisition. As a percentage of total net revenues, operational expenses decreased from 17.4% in the third quarter of 2013 to 16.8% in the third quarter of 2014, primarily due to a reduction in travel and communications expenses in the third quarter of 2014 compared to the third quarter of 2013 and the effects of foreign exchange volatility.

*Depreciation and amortization expenses.* Depreciation and amortization expenses as a component of cost of revenue for the third quarter of 2014 were \$11.2 million, down \$0.9 million, or 7.5%, from the third quarter of 2013. Depreciation and amortization expenses as a percentage of total net revenues decreased from 2.3% in the third quarter of 2013 to 1.9% in the third quarter of 2014. These decreases were primarily due to an increase in fully depreciated assets since the end of the third quarter of 2013 at our service delivery centers located in India, the Philippines and the Americas and to the effects of foreign exchange volatility. These decreases were partially offset by depreciation and amortization expenses resulting from the expansion of certain existing facilities, from the addition of new service delivery centers in India and from our regulatory affairs acquisition.

*Selling, general and administrative expenses.* The following table sets forth the components of our selling, general and administrative, or SG&A, expenses:

	<b>Three months ended</b>		<b>As a percentage of total net revenues</b>	
	<b>September 30, 2013</b>	<b>September 30, 2014</b>	<b>2013</b>	<b>2014</b>
	<b>(dollars in millions)</b>			
Personnel expenses	\$ 83.6	\$ 111.4	15.6%	18.9%
Operational expenses	31.3	39.6	5.9	6.7
Depreciation and amortization	2.1	2.1	0.4	0.4
<b>Selling, general and administrative expenses</b>	<b>\$ 117.0</b>	<b>\$ 153.1</b>	<b>21.9%</b>	<b>26.0%</b>

SG&A expenses in the third quarter of 2014 were \$153.1 million, up \$36.1 million, or 30.9%, from the third quarter of 2013. SG&A expenses as a percentage of total net revenues increased from 21.9% in the third quarter of 2013 to 26.0% in the third quarter of 2014. SG&A expenses increased primarily as a result of our continued investments in client-facing teams and subject matter experts through the hiring of seasoned, higher-cost personnel in targeted markets such as the United States and Europe and certain industry verticals namely, banking and financial services, insurance, consumer product goods and life sciences. Wage inflation also contributed to the increase in SG&A expenses in the third quarter of 2014. As a result, our sales and marketing expenses as a percentage of net revenues were approximately 6.8% in the third quarter of 2014, up from approximately 4.7% in the third quarter of 2013.

Of the total increase in SG&A expenses, \$2.3 million is attributable to our regulatory affairs acquisition. Additionally, travel costs related to sales and marketing activities and fees for professional services related to strategic initiatives contributed to higher SG&A expenses. These increases were partially offset by a lower reserve for doubtful receivables in the third quarter of 2014 compared to the third quarter of 2013 and by the effects of foreign exchange volatility.

*Personnel expenses.* Personnel expenses as a percentage of total net revenues in the third quarter of 2014 were 18.9%, up from 15.6% in the third quarter of 2013. Personnel expenses as a component of SG&A expenses were \$111.4 million in the third quarter of 2014, up \$27.8 million, or 33.3%, from the third quarter of 2013. Our sales team personnel expenses increased by 61.5%, primarily driven by the addition of approximately 45 client-facing personnel in the third quarter of 2014. Our regulatory affairs acquisition also contributed an additional \$1.6 million to personnel expenses. Stock-based compensation resulted in a \$2.4 million increase in personnel expenses in the third quarter of 2014 compared to the third quarter of 2013. Additionally, wage inflation and an increase in our headcount contributed to higher personnel costs. These increases were partially offset by the effects of foreign exchange volatility.

*Operational expenses.* Operational expenses as a percentage of total net revenues increased from 5.9% in the third quarter of 2013 to 6.7% in the third quarter of 2014. This increase was primarily attributable to higher marketing expenditures, increased sales-related travel and fees for professional services. Operational expenses as a component of SG&A expenses increased by \$8.3 million, or 26.4%, in the third quarter of 2014 compared to the third quarter of 2013. Of this increase, approximately \$0.6 million, or 7.7%, is attributable to our regulatory affairs acquisition. The increase in operational expenses was partially offset by a \$3.2 million reduction in the reserve for doubtful receivables in the third quarter of 2014 compared to the third quarter of 2013 and by the effects of foreign exchange volatility in the third quarter of 2014.

**Table of Contents**

*Depreciation and amortization.* Depreciation and amortization expenses as a percentage of total net revenues were 0.4% in the third quarter of 2014, unchanged from the third quarter of 2013. An increase in fully depreciated assets since the end of the third quarter of 2013 at our facilities located in India, the Philippines and the Americas and the effects of foreign exchange volatility resulted in lower depreciation and amortization expenses. This decrease was offset by depreciation and amortization expenses resulting from the expansion of certain existing facilities, from the addition of new facilities in India, and from our regulatory affairs acquisition.

*Amortization of acquired intangibles.* Non-cash charges on account of the amortization of acquired intangibles were \$8.0 million in the third quarter of 2014, up from \$5.9 million in the third quarter of 2013. Our regulatory affairs acquisition resulted in additional amortization expenses of \$2.2 million in the third quarter of 2014. This increase was partially offset by a decline of \$0.2 million in the amortization expense of intangibles arising out of our reorganization in 2004, when we began operating as an independent company. In each case, the amortization was consistent with the applicable estimated useful life of the acquired intangible asset.

*Other operating (income) expense, net.* Other operating income, net of expenses was \$0.4 million in the third quarter of 2014, down from \$3.2 million in the third quarter of 2013. In the third quarter of 2013, we recorded a gain of \$2.2 million due to changes in the fair value of earn-out consideration relating to certain acquisitions. No such gains or losses were recognized in the third quarter of 2014.

*Income from operations.* As a result of the foregoing factors, income from operations decreased by \$13.1 million to \$72.9 million in the third quarter of 2014 from \$86.0 million in the third quarter of 2013. As a percentage of total net revenues, income from operations decreased from 16.1% in the third quarter of 2013 to 12.4% in the third quarter of 2014.

*Foreign exchange (gains) losses, net.* We recorded a net foreign exchange loss of \$4.7 million in the third quarter of 2014, compared to a net foreign exchange gain of \$10.8 million in the third quarter of 2013, primarily due to the re-measurement of our non-functional currency assets and liabilities and related foreign exchange contracts resulting from the depreciation of the Euro against the U.S. dollar and the appreciation of the Chinese Yuan against the U.S. dollar, each in the third quarter of 2014, and the depreciation of the Indian rupee against the U.S. dollar in the third quarter of 2013.

*Other income (expense), net.* The following table sets forth the components of other income (expense), net:

	Three months ended September 30,		Percentage Change
	2013	2014	Increase/(Decrease) 2014 vs. 2013
	(dollars in millions)		
Interest income	\$ 4.4	\$ 1.6	(63.3)%
Interest expense	(8.1)	(9.0)	10.5
Provision reversed for loss on divestitures	0.1		(100.0)
Other income (expense)	0.2	1.0	416.3
<b>Other income (expense), net</b>	<b>\$ (3.5)</b>	<b>\$ (6.4)</b>	<b>86.4%</b>
	<b>(0.6)%</b>	<b>(1.1)%</b>	

**Other income (expense), net as a percentage of total net revenues**

Our net other expenses increased by \$3.0 million in the third quarter of 2014 compared to the third quarter of 2013, primarily due to a \$2.8 million decrease in interest income and a \$0.9 million increase in interest expense in the third quarter of 2014 compared to the third quarter of 2013. Interest expense increased as a result of higher outstanding borrowings in the third quarter of 2014 compared to the third quarter of 2013. Further, the weighted average rate of interest on our debt decreased from 3.5% in the third quarter of 2013 to 3.3% in the third quarter of 2014. Our interest income decreased by \$2.8 million in the third quarter of 2014 primarily as a result of higher account balances in jurisdictions in which we earn lower interest rates compared to the third quarter of 2013. This decrease was partially offset by \$1.0 million in interest income on an income tax refund in the third quarter of 2014.

*Income before equity method investment activity, net and income tax expense.* As a result of the foregoing factors, income before equity method investment activity, net and income tax expense decreased by \$31.6 million in the third quarter of 2014 compared to the third quarter of 2013. As a percentage of net revenues, income before equity method investment activity, net and income tax decreased from 17.4% in the third quarter of 2013 to 10.5% in the third quarter of 2014.

**Table of Contents**

*Equity-method investment activity, net.* Equity-method investment activity, net represents our share of gain or loss from our non-consolidated affiliate, NIIT Uniqua, a joint venture in Asia.

*Income before income tax expense.* As a result of the foregoing factors, income before income tax expense decreased by \$31.6 million. As a percentage of net revenues, income before income tax expense decreased from 17.5% in the third quarter of 2013 to 10.5% in the third quarter of 2014.

*Income tax expense.* Our income tax expense decreased from \$21.9 million in the third quarter of 2013 to \$15.1 million in the third quarter of 2014, representing an effective tax rate, or ETR, of 24.5% in the third quarter of 2014, up from 23.8% in the third quarter of 2013. The reduction in tax expense is due to lower pre-tax profits in the third quarter of 2014 compared to the third quarter of 2013. The increase in our effective tax rate is driven by certain one-time benefits recorded in the third quarter of last year, which have been partially offset by the continued growth of our operations in lower tax and tax-exempt locations, primarily in India.

*Net income.* As a result of the foregoing factors, net income decreased by \$24.8 million from \$71.4 million in the third quarter of 2013 to \$46.7 million in the third quarter of 2014. As a percentage of net revenues, our net income decreased from 13.4% of net revenues in the third quarter of 2013 to 7.9% of net revenues in the third quarter of 2014.

*Net income attributable to noncontrolling interest.* Noncontrolling interest primarily refers to the profit or loss associated with our noncontrolling partners' interest in the operations of Genpact Netherlands B.V. Net income attributable to noncontrolling interest decreased from \$1.2 million in the third quarter of 2013 to \$0 in the third quarter of 2014. This decrease was the result of our purchase of the noncontrolling partner's interests in Genpact Netherlands B.V., over which we now have 100% control.

*Net income attributable to Genpact Limited common shareholders.* As a result of the foregoing factors, net income attributable to our common shareholders decreased by \$23.6 million from \$70.3 million in the third quarter of 2013 to \$46.7 million in the third quarter of 2014. As a percentage of net revenues, net income attributable to Genpact Limited common shareholders decreased from 13.1% in the third quarter of 2013 to 7.9% in the third quarter of 2014.

**Nine Months Ended September 30, 2014 Compared to the Nine Months Ended September 30, 2013**

*Net revenues.* Our net revenues were \$1,677.9 million in the nine months ended September 30, 2014, up \$104.4 million, or 6.6%, from \$1,573.5 million in the nine months ended September 30, 2013. Adjusted for foreign exchange, which had an adverse impact on our net revenues in the nine months ended September 30, 2014, our net revenues grew 7.4% compared to the nine months ended September 30, 2013. The growth in our net revenues was primarily driven by an increase in BPO services delivered to our Global Clients, an increase in IT services delivered to both our Global Clients and GE, and our regulatory affairs acquisition. Our annualized net revenue per employee for the nine months ended September 30, 2014 was \$35,400, compared to \$35,800 in the nine months ended September 30, 2013. The mild decline in revenue per employee is due in part to an increase in personnel deployed primarily during the first half of 2014 to manage the complex transition periods associated with certain large, transformational deals. Our average headcount increased to approximately 63,900 in the nine months ended September 30, 2014 from approximately 58,900 in the nine months ended September 30, 2013.

		<b>Percentage Change</b>
<b>Nine months ended September 30,</b>		<b>Increase/(Decrease)</b>
<b>2013</b>	<b>2014</b>	<b>2014 vs. 2013</b>

	(dollars in millions)		
BPO Services	\$ 1,187.4	\$ 1,269.6	6.9%
IT Services	386.1	408.4	5.8
<b>Total net revenues</b>	<b>\$ 1,573.5</b>	<b>\$ 1,677.9</b>	<b>6.6%</b>

Net revenues from BPO services in the nine months ended September 30, 2014 were \$1,269.6 million, up \$82.1 million, or 6.9%, from \$1,187.4 million in the nine months ended September 30, 2013, due to an increase in revenues from our Global Clients, particularly for consulting services, finance and accounting services and core vertical operations, and to revenues derived from our regulatory affairs acquisition. Net revenues from IT services were \$408.4 million in the nine months ended September 30, 2014, up \$22.3 million, or 5.8%, from \$386.1 million in the nine months ended September 30, 2013 as a result of an increase in IT services delivered to both our Global Clients and GE.

Net revenues from BPO services as a percentage of total net revenues increased to 75.7% in the nine months ended September 30, 2014, up from 75.5% in the nine months ended September 30, 2013, with a corresponding decline in the percentage of total net revenues attributable to IT services.

**Table of Contents**

	Nine months ended September 30,		Percentage Change
	2013	2014	Increase/(Decrease) 2014 vs. 2013
	(dollars in millions)		
Global Clients	\$ 1,216.9	\$ 1,330.7	9.4%
GE	356.7	347.2	(2.6)
<b>Total net revenues</b>	<b>\$ 1,573.5</b>	<b>\$ 1,677.9</b>	<b>6.6%</b>

Net revenues from Global Clients in the nine months ended September 30, 2014 were \$1,330.7 million, up \$113.8 million, or 9.4%, from \$1,216.9 million in the nine months ended September 30, 2013. This increase was primarily driven by growth in four of our targeted verticals – namely, life sciences, consumer product goods, insurance and capital markets – including revenues derived from our regulatory affairs acquisition. As a percentage of total net revenues, net revenues from Global Clients increased from 77.3% in the nine months ended September 30, 2013 to 79.3% in the nine months ended September 30, 2014. BPO and IT services revenues from Global Clients grew by 10.6% and 5.6%, respectively.

Net revenues from GE were \$347.2 million in the nine months ended September 30, 2014, down \$9.4 million, or 2.6%, from the nine months ended September 30, 2013 primarily as a result of an expected decline in BPO services delivered to GE which was partially offset by growth in IT and consulting projects. Net revenues from GE as a percentage of our total net revenues declined from 22.7% in the nine months ended September 30, 2013 to 20.7% in the nine months ended September 30, 2014.

Net revenues by geographic region based on the location of our service delivery centers are as follows:

	Nine months ended September 30,		Percentage change
	2013	2014	Increase/(Decrease) 2014 vs. 2013
	(dollars in millions)		
India	\$ 1,034.2	\$ 1,104.8	6.8%
Americas	214.3	227.2	6.0
Asia, other than India	166.4	172.5	3.7
Europe	158.6	173.4	9.3
<b>Total net revenues</b>	<b>\$ 1,573.5</b>	<b>\$ 1,677.9</b>	<b>6.6%</b>

Net revenues grew in all of our geographic regions in the nine months ended September 30, 2014. Net revenues from service delivery centers located in Europe grew the most, contributing \$173.4 million to total net revenues in the nine months ended September 30, 2014, up \$14.8 million, or 9.3%, from the nine months ended September 30, 2013. Approximately \$5.5 million of this increase was attributable to our regulatory affairs acquisition. Total net revenues from India-based service delivery centers were \$1,104.8 million in the nine months ended September 30, 2014, up 6.8% from the nine months ended September 30, 2013. A portion of net revenues attributable to India-based service delivery centers includes net revenues for services performed from service delivery centers outside India that are managed by India-based service delivery leaders or at clients' premises outside India by personnel normally based in India. Service delivery centers located in the Americas contributed \$227.2 million to total net revenues in the nine

Edgar Filing: Genpact LTD - Form 10-Q

months ended September 30, 2014, up \$12.9 million, or 6.0%, from the nine months ended September 30, 2013. Approximately \$6.8 million of this increase was attributable to our regulatory affairs acquisition. Net revenues from service delivery centers located in Asia, other than India primarily China and the Philippines were \$172.5 million in the nine months ended September 30, 2014, up 3.7% from the nine months ended September 30, 2013.

*Cost of revenue and gross profit.* The following table sets forth the components of our cost of revenue and the resulting gross profit:

	Nine months ended September 30,		As a percentage of total net revenues	
	2013	2014	2013	2014
	(dollars in millions)			
Personnel expenses	\$ 671.5	\$ 701.5	42.7%	41.8%
Operational expenses	265.9	284.3	16.9	16.9
Depreciation and amortization	36.3	33.1	2.3	2.0
<b>Cost of revenue</b>	<b>\$ 973.7</b>	<b>\$ 1,018.9</b>	<b>61.9%</b>	<b>60.7%</b>
<b>Gross profit</b>	<b>599.8</b>	<b>659.0</b>	<b>38.1%</b>	<b>39.3%</b>

**Table of Contents**

Our gross margin increased from 38.1% in the nine months ended September 30, 2013 to 39.3% in the nine months ended September 30, 2014. This increase is primarily attributable to improved operational efficiencies, including effective deployment and use of operations personnel, and the effects of foreign exchange volatility. The impact of these factors was partially offset by the effects of wage inflation.

Cost of revenue in the nine months ended September 30, 2014 was \$1,018.9 million, up \$45.2 million, or 4.6%, from the nine months ended September 30, 2013. Of this increase, approximately \$16.9 million, or 37.4%, is attributable to acquisitions completed in 2013 and 2014. Wage inflation and an increase in personnel expenses due to an increase in our operational headcount and increased use of subcontractors for service delivery also contributed to higher cost of revenue in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013. These increases were partially offset by lower stock-based compensation costs, by the effects of foreign exchange volatility, and by the improved operational efficiencies described above in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013.

*Personnel expenses.* Personnel expenses as a percentage of total net revenues decreased from 42.7% in the nine months ended September 30, 2013 to 41.8% in the nine months ended September 30, 2014, primarily due to improved operational efficiencies, including more effective deployment and use of operations personnel, the increased use of subcontractors for service delivery, the effects of foreign exchange volatility and a decrease in stock-based compensation expenses. The impact of these factors was partially offset by the effects of wage inflation, an increase in our operational headcount and the acquisitions we completed in 2013 and 2014. As a result, personnel expenses for the nine months ended September 30, 2014 were \$701.5 million, up \$30.0 million, or 4.5%, from \$671.5 million in the nine months ended September 30, 2013.

*Operational expenses.* Operational expenses for the nine months ended September 30, 2014 were \$284.3 million, up \$18.4 million, or 6.9%, from the nine months ended September 30, 2013. Approximately \$5.8 million, or 31.3%, of the increase is attributable to acquisitions completed during 2013 and 2014. Excluding the impact of acquisitions completed in 2013 and 2014, subcontractor costs increased by approximately \$16.1 million and business travel expenses increased by approximately \$2.1 million in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013. These increases were partially offset by the effects of foreign exchange volatility and a reduction in infrastructure and communications expenses. As a result, operational expenses as a percentage of total net revenues were unchanged at 16.9% in the nine months ended September 2014 compared to the nine months ended September 2013.

*Depreciation and amortization expenses.* Depreciation and amortization expenses as a component of cost of revenue in the nine months ended September 30, 2014 were \$33.1 million, down \$3.2 million, or 8.9%, from the nine months ended September 30, 2013. These decreases were primarily due to an increase in fully depreciated assets since September 30, 2013 at our service delivery centers located in India, the Philippines and the Americas and the effects of foreign exchange volatility. These decreases were partially offset by depreciation and amortization expenses resulting from the expansion of certain existing facilities, from the addition of new service delivery centers in India and from acquisitions completed in 2013 and 2014.

*Selling, general and administrative expenses.* The following table sets forth the components of our selling, general and administrative, or SG&A, expenses:

	<b>As a percentage of total net</b>
<b>Nine months ended September 30,</b>	<b>revenues</b>

	<b>2013</b>	<b>2014</b>	<b>2013</b>	<b>2014</b>
	<b>(dollars in millions)</b>			
Personnel expenses	\$ 251.4	\$ 302.1	16.0%	18.0%
Operational expenses	90.9	110.0	5.8	6.6
Depreciation and amortization	6.4	6.3	0.4	0.4
<b>Selling, general and administrative expenses</b>	<b>\$ 348.6</b>	<b>\$ 418.4</b>	<b>22.2%</b>	<b>24.9%</b>

SG&A expenses for the nine months ended September 30, 2014 were \$418.4 million, up \$69.7 million, or 20.0%, from the nine months ended September 30, 2013. Investments in client-facing teams and subject matter experts through the hiring of seasoned, higher-cost personnel in targeted markets such as the United States and Europe and industry verticals namely banking and financial services, insurance, consumer product goods and life sciences resulted in higher SG&A expenses. These investments are in line with our plans to bring sales and marketing expenses in the range of 6% to 6.5% of revenue. Wage inflation also contributed to the increase in SG&A expenses in the nine months ended September 30, 2014.

---

**Table of Contents**

Of the total increase in SG&A expenses, approximately \$5.2 million, or 7.4%, is attributable to acquisitions completed in 2013 and 2014. Additionally, higher expenditures on marketing, acquisition-related expenses, fees for professional services related to strategic initiatives, and sales-related travel also contributed to higher SG&A expenses in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013. These increases were partially offset by a lower reserve for doubtful receivables in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 and by the effects of foreign exchange volatility.

*Personnel expenses.* Personnel expenses as a component of SG&A expenses were \$302.1 million in the nine months ended September 30, 2014, up \$50.7 million, or 20.2%, from the nine months ended September 30, 2013. Our sales team personnel expenses increased by 36.2%, primarily driven by the addition of 100+ client-facing personnel in 2014. Another \$3.1 million of the increase is due to acquisitions completed in 2013 and 2014. Wage inflation and an increase in our headcount also resulted in higher personnel costs in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013. This increase was partially offset by the effects of foreign exchange volatility. As a result, personnel expenses as a percentage of total net revenues in the nine months ended September 2014 were 18.0%, up from 16.0% in the nine months ended September 2013.

*Operational expenses.* Operational expenses as a component of SG&A expenses increased by \$19.1 million, or 21.0%, in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013. Higher sales-related travel and professional services expenses resulted in higher operational expenses in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013. Of this increase, \$1.5 million is attributable to acquisitions completed in 2013 and 2014. We also incurred acquisition-related expenses of \$2.0 million in the nine months ended September 30, 2014 for our regulatory affairs acquisition. These increases were partially offset by a \$6.6 million decline in the reserve for doubtful receivables in the nine months ended September 30, 2014, an expense of \$1.1 million relating to the amendment of our credit facility in 2013 and the effects of foreign exchange volatility. As a result, our operational expenses as a percentage of total net revenues increased from 5.8% in the nine months ended September 30, 2013 to 6.6% in the nine months ended September 30, 2014.

*Depreciation and amortization.* Depreciation and amortization expenses as a percentage of total net revenues were unchanged at 0.4%. Fully depreciated assets increased since September 30, 2013 at our facilities located in India, the Philippines and the Americas, and the effects of foreign exchange volatility resulted in lower depreciation and amortization expenses in the nine months ended September 30, 2014. This decrease was offset by depreciation and amortization expenses resulting from the expansion of certain existing facilities in India, from the addition of new facilities and from acquisitions completed in 2013 and 2014.

*Amortization of acquired intangibles.* Non-cash charges on account of the amortization of acquired intangibles were \$20.6 million in the nine months ended September 30, 2014, up from \$17.6 million in the nine months ended September 30, 2013. Acquisitions we completed during 2013 and 2014 resulted in additional amortization expenses of \$3.6 million in the nine months ended September 30, 2014. This increase was partially offset by a \$0.8 million decline in the amortization expense of intangibles arising out of our reorganization in 2004, when we began operating as an independent company. In each case, the amortization was consistent with the applicable estimated useful life of the acquired intangible asset.

*Other operating (income) expense, net.* Other operating income, net of expenses, was \$3.1 million in the nine months ended September 30, 2014, down from \$4.3 million in the nine months ended September 30, 2013. In the nine months ended September 30, 2013, we recorded a \$2.4 million non-recurring provision for impairment against certain capital assets in India that were no longer strategic to our growth. This was offset by a \$2.3 million lower gain resulting from changes in earn-out consideration payable in connection with certain acquisitions. The balance of the decrease is attributable to lower shared services income, which declined from \$2.3 million in the nine months ended

September 30, 2013 to \$0.9 million in the nine months ended September 30, 2014.

*Income from operations.* As a result of the foregoing factors, income from operations decreased by \$14.7 million to \$223.2 million in the nine months ended September 30, 2014 from \$237.9 million in the nine months ended September 30, 2013. As a percentage of total net revenues, income from operations decreased from 15.1% in the nine months ended September 30, 2013 to 13.3% in the nine months ended September 30, 2014.

*Foreign exchange (gains) losses, net.* We recorded a net foreign exchange loss of \$12.1 million in the nine months ended September 30, 2014, compared to a net foreign exchange gain of \$24.6 million in the nine months ended September 30, 2013. The net foreign exchange loss in the nine months ended September 30, 2014 is primarily on account of the re-measurement of our non-functional currency assets and liabilities and related foreign exchange contracts resulting from the appreciation of the Indian rupee against the U.S. dollar and the depreciation of the euro against the U.S. dollar. The net foreign exchange gain in the nine months ended September 30, 2013 is primarily due to depreciation of the Indian rupee against the U.S. dollar in the nine months ended September 30, 2013.

**Table of Contents**

*Other income (expense), net.* The following table sets forth the components of other income (expense), net:

	Nine months ended September 30,		Percentage Change
	2013	2014	Increase/(Decrease) 2014 vs. 2013
	(dollars in million)		
Interest income	\$ 14.1	\$ 3.6	(74.6)%
Interest expense	(30.9)	(24.4)	(21.0)
Provision (created) for loss on divestures	(3.5)		(100.0)
Other income	1.2	1.3	14.9
<b>Other income (expense), net</b>	<b>\$ (19.1)</b>	<b>\$ (19.5)</b>	<b>2.0%</b>

**Other income (expense), net as a percentage of total net revenues**

(1.2)%                      (1.2)%

Our net other expenses increased by \$0.4 million in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 primarily due to a \$3.5 million provision for losses on the divestitures of Clearbizz B.V. and Gantthead.com., Inc. created in the nine months ended September 30, 2013. This decrease was partially offset by an increase in our net interest expense in the nine months ended September 30, 2014. Our net interest expense increased by \$4.1 million as the result of a \$6.5 million decrease in interest expense and a \$10.5 million decrease in interest income in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013. The decrease in interest expense was the result of an expense of \$3.1 million in the nine months ended September 30, 2013 relating to the amendment of our credit facility and a lower interest expense of \$2.3 million in the nine months ended September 30, 2014 due to a lower interest rate on the amended facility. Further, the weighted average rate of interest on our debt decreased from 3.9% in the nine months ended September 30, 2013 to 3.4% in the nine months ended September 30, 2014. Our interest income also decreased by \$10.5 million in the nine months ended September 30, 2014 primarily as a result of higher account balances in jurisdictions in which we earn lower interest rates during the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013.

*Income before equity method investment, activity, net and income tax expense.* As a result of the foregoing factors, income before equity method investment activity, net and income tax expense decreased by \$51.8 million in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013. As a percentage of net revenues, income before equity method investment activity, net and income tax expense decreased from 15.5% in the nine months ended September 30, 2013 to 11.4% in the nine months ended September 30, 2014.

*Equity-method investment activity, net.* Equity-method investment activity, net represents our share of gain or loss from our non-consolidated affiliates, NGEN Media Services Private Limited, or NGEN, a joint venture with NDTV Networks Plc., and NIIT Uniqua, a joint venture in Asia. In March 2013, we acquired the remaining equity interest in NGEN.

*Income before income tax expense.* As a result of the foregoing factors, our income before income tax expense decreased by \$51.9 million. As a percentage of net revenues, income before income tax expense decreased from 15.5% of net revenues in the nine months ended September 30, 2013 to 11.4% of net revenues in the nine months ended September 30, 2014.

*Income tax expense.* Our income tax expense decreased from \$58.4 million in the nine months ended September 30, 2013 to \$45.3 million in the nine months ended September 30, 2014, representing an ETR of 23.6% in the nine months ended September 30, 2014, down from 24.4% in the nine months ended September 30, 2013. The reduction in tax expense is due to lower pre-tax profits in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013. The improvement in our ETR is primarily a consequence of the continued growth of our operations in lower-tax and tax-exempt locations, primarily in India.

*Net income.* As a result of the foregoing factors, net income decreased by \$38.7 million from \$185.1 million in the nine months ended September 30, 2013 to \$146.4 million in the nine months ended September 30, 2014. As a percentage of net revenues, our net income decreased from 11.8% in the nine months ended September 30, 2013 to 8.7% in the nine months ended September 30, 2014.

*Net income attributable to noncontrolling interest.* Noncontrolling interest primarily refers to profit or loss associated with our noncontrolling partners' interest in the operations of Genpact Netherlands B.V. and the noncontrolling shareholders' interest in the operations of Hello Communications (Shanghai) Co., Ltd. Net income attributable to noncontrolling interest decreased from \$4.3 million in the nine months ended September 30, 2013 to \$0.2 million in the nine months ended September 30, 2014. This decrease was the result of our purchase of the noncontrolling interests in Genpact Netherlands B.V. in the third quarter of 2014, over which we now have 100% control, and to our divestiture of Hello Communications (Shanghai) Co. Ltd. in February 2013.

*Net income attributable to Genpact Limited common shareholders.* As a result of the foregoing factors, net income attributable to our common shareholders decreased by \$34.6 million from \$180.9 million in the nine months ended September 30, 2013 to \$146.3 million in the nine months ended September 30, 2014. As a percentage of net revenues, net income attributable to Genpact Limited common shareholders decreased from 11.5% in the nine months ended September 30, 2013 to 8.7% in the nine months ended September 30, 2014.

**Table of Contents****Liquidity and Capital Resources****Overview**

Information about our financial position as of December 31, 2013 and September 30, 2014 is presented below:

	As of December 31, 2013	As of September 30, 2014	Percentage Change Increase/(Decrease)
	(dollars in millions)		
Cash and cash equivalents	\$ 571.3	\$ 399.2	(30.1)%
Short term deposits		25.0	NM*
Current portion of long-term debt	4.3	4.3	0.4
Long-term debt, less current portion	653.6	650.4	(0.5)
Short-term borrowings		165.0	NM*
Genpact Limited total shareholders equity	\$ 1,322.7	\$ 1,248.5	(5.6)%

\* Not Measurable

**Financial Condition**

We finance our operations and our expansion, including acquisitions, with cash from operations and borrowing facilities.

Our cash and cash equivalents were \$399.2 million as of September 30, 2014, compared to \$571.3 million as of December 31, 2013. Our cash and cash equivalents as of September 30, 2014 were comprised of (a) \$93.0 million in cash in current accounts across all operating locations to be used for working capital and immediate capital requirements, (b) \$305.4 million in deposits with banks to be used for medium-term planned expenditures and capital requirements and (c) \$0.8 million in restricted cash balances. Restrictions primarily consist of margin balances against bank guarantees and deposits for foreign currency advances on which the bank has created a lien. We also had short term deposits of \$25.0 million as of September 30, 2014, compared to \$0 as of December 31, 2013.

As of September 30, 2014, \$376.6 million of the \$399.2 million in cash and cash equivalents was held by our foreign (non-Bermuda) subsidiaries. We intend to either permanently reinvest the cash held by our foreign subsidiaries or expect to be able to repatriate it in a tax-free manner. The amount of cash that can be repatriated in a tax-free manner is not ascertainable.

We expect that in the future our cash from operations, cash reserves and debt capacity will be sufficient to finance our operations as well as our growth and expansion. Our working capital needs are primarily to finance our payroll and other administrative and information technology expenses in advance of the receipt of accounts receivable. Our capital requirements include opening new service delivery centers and financing acquisitions.

Cash flows from operating, investing and financing activities, as reflected in our consolidated statements of cash flows, are summarized in the following table:

	Nine Months Ended September 30,		Percentage Change
	2013	2014	Increase/(Decrease)
	(dollars in million)		2014 vs. 2013
Net cash provided by (used for)			
Operating activities	\$ 233.2	\$ 178.8	(23.3)%
Investing activities	(87.7)	(196.3)	124.0
Financing activities	(70.1)	(152.6)	117.8
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>\$ 75.5</b>	<b>\$ (170.2)</b>	<b>(325.4)%</b>

*Cash flows from operating activities.* Our net cash generated from operating activities was \$178.8 million in the nine months ended September 30, 2014, compared to \$233.2 million in the nine months ended September 30, 2013. This decrease was primarily the result of a \$54.3 million decrease in net income adjusted for amortization, depreciation and other non-cash items in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 mainly due to the impacts of foreign exchange fluctuations and the investments in sales and marketing described above. Further, up-front investments in certain large deals resulted in an additional cash outflow of approximately \$9.0 million in the nine months ended September 30, 2014. We also paid a one-time intercompany dividend tax of \$5.0 million in the nine months ended September 30, 2014 compared to the receipt of a one-time tax refund in the nine months ended September 30, 2013. Further, our cash inflow in the nine months ended September 30, 2014 was lower because the Government of India withheld \$9.6 million of tax refunds owed to the Company for prior periods in partial satisfaction of the \$43 million May 2014 assessment order for certain transactions that occurred in 2009 and 2010 which we are appealing. The increased outflow was partially offset by the improved collection of client receivables in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013, resulting in a \$6.3 million lower investment in accounts receivable and higher accruals, primarily for employee costs, recorded in the nine months ended September 30, 2014.

---

**Table of Contents**

*Cash flows from investing activities.* Our net cash used for investing activities was \$196.3 million in the nine months ended September 30, 2014, compared to \$87.7 million in the nine months ended September 30, 2013. This increase in net cash used for investing activities was primarily due to the payment of \$123.7 million, net of cash acquired, for our regulatory affairs acquisition in the nine months ended September 30, 2014 compared to the payment of \$49.2 million in the nine months ended September 30, 2013, net of cash acquired, for the acquisitions consummated during that period. The balance of the increase in net cash used for investing activities was due to higher payments for purchases of property, plant and equipment (net of sales proceeds) of \$47.6 million in the nine months ended September 30, 2014 compared to \$34.1 million in the nine months ended September 30, 2013 and higher short-term deposits (net of redemptions) of \$25.0 million in the nine months ended September 30, 2014 compared to \$3.3 million in the nine months ended September 30, 2013.

*Cash flows from financing activities.* Our net cash used for financing activities was \$152.6 million in the nine months ended September 30, 2014 compared to \$70.1 million in the nine months ended September 30, 2013. This increase was primarily due to the payment of \$302.6 million for the purchase of Company common shares and related expenses of \$2.5 million in the nine months ended September 30, 2014. Lower proceeds from the issuance of common shares under stock-based compensation plans in the nine months ended September 30, 2014 also accounted for a \$23.5 million reduction in cash inflows in the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013. Additionally, payments for net settlement of stock-based awards were \$7.6 million higher in the nine months ended September 30, 2014 than in the nine months ended September 30, 2013. The impact of these items on cash flows was offset by higher proceeds from short-term borrowings (net of repayments) of \$165.0 million in the nine months ended September 30, 2014 compared to the repayment of short-term borrowings (net of proceeds) of \$80.0 million in the nine months ended September 30, 2013 and by the payment of \$8.1 million in expenses relating to the amendment of our credit facility in the nine months ended September 30, 2013.

**Financing Arrangements (Credit Facility)**

Our credit agreement provides for a term loan of \$675.0 million. Total long-term debt, excluding capital lease obligations, was \$654.7 million as of September 30, 2014, compared to \$657.9 million as of December 31, 2013. As of December 31, 2013 and September 30, 2014, the term loan bears interest at LIBOR (LIBOR floor of 0.75%) plus an applicable margin of 2.75% p.a. Indebtedness under the loan agreement is secured by certain assets. The amount outstanding on the term loan as of September 30, 2014 will be repaid through quarterly payments of 0.25% of the principal amount of \$675.0 million, and the balance will be repaid upon the maturity of the term loan on August 30, 2019.

We finance our short-term working capital requirements through cash flows from operations and credit facilities from banks and financial institutions. As of September 30, 2014, short-term credit facilities available to us, which are governed by the same agreement as our long-term credit facility, aggregated \$250.0 million. As of December 31, 2013 and September 30, 2014, a total of \$4.4 million and \$167.2 million, respectively, was utilized, of which \$0 and \$165.0 million, respectively, constituted funded drawdown and \$4.4 million and \$2.2 million, respectively, constituted non-funded drawdown.

Our short-term credit facility will expire in August 2017. The funded drawdown amount bears interest at LIBOR plus a margin of 2.50% as of both December 31, 2013 and September 30, 2014. The unutilized amount on the facility bears a commitment fee of 0.50%. Indebtedness under these facilities is secured by certain assets of the Company, and the credit agreement contains certain covenants, including a maximum leverage covenant that becomes effective only if the revolving facility is drawn for \$50.0 million or more. During the nine months ended September 30, 2014, we were in compliance with all of the financial covenants.

In addition, we have fund-based and non-fund-based short-term credit facilities with banks, which are available for operational requirements in the form of overdrafts, letters of credit, guarantees and short-term loans. As of December 31, 2013 and September 30, 2014, the limits available were \$13.9 million and \$14.7 million, respectively, out of which \$6.7 million and \$7.8 million, was utilized, constituting non-funded drawdown.

**Off-Balance Sheet Arrangements**

Our off-balance sheet arrangements consist of foreign exchange contracts and certain operating leases. For additional information, see Part I, Item 1A Risk Factors Currency exchange rate fluctuations in various currencies in which we do business, especially the Indian rupee and the U.S. dollar, could have a material adverse effect on our business, results of operations and financial condition in our Annual Report on Form 10-K for the year ended December 31, 2013, the section titled Contractual Obligations below and note 7 in Part I Financial Statements.

**Table of Contents****Contractual Obligations**

The following table sets forth our total future contractual obligations as of September 30, 2014:

	<b>Total</b>	<b>Less than 1 year</b>	<b>1-3 years</b>	<b>3-5 years</b>	<b>After 5 years</b>
Long-term debt	\$ 768.2	\$ 27.8	\$ 55.1	\$ 685.3	\$
- <i>Principal payments</i>	654.7	4.3	8.6	641.8	
- <i>Interest payments*</i>	113.6	23.6	46.5	43.5	
Short-term borrowings	169.2	169.2			
- <i>Principal payments</i>	165.0	165.0			
- <i>Interest payments**</i>	4.2	4.2			
Capital leases	5.4	2.1	2.7	0.7	
- <i>Principal payments</i>	4.4	1.5	2.2	0.6	
- <i>Interest payments</i>	1.1	0.5	0.4	0.1	
Operating leases	143.4	37.0	55.4	31.1	19.9
Purchase obligations	21.8	21.8			
Capital commitments net of advances	5.9	5.9			
Earn-out Consideration	28.1	12.1	16.0		
- <i>Reporting Date Fair Value</i>	24.3	11.3	13.0		
- <i>Interest</i>	3.8	0.9	3.0		
Other long-term liabilities	116.4	70.2	44.6	1.6	
<b>Total contractual cash obligations</b>	<b>\$ 1,258.5</b>	<b>\$ 346.0</b>	<b>\$ 173.8</b>	<b>\$ 718.7</b>	<b>\$ 19.9</b>

\* Our interest payments on long-term debt represent estimated payments based on the prevailing interest rate as of September 30, 2014.

\*\* Our interest payments on short-term debt represent estimated payments based on the prevailing interest rate as of September 30, 2014 and our expectation for the repayment of such debt.

---

**Table of Contents****Recent Accounting Pronouncements***Recently adopted accounting pronouncements*

For a description of recently adopted accounting pronouncements, see Note 2 Recently adopted accounting pronouncements under Item 1 Financial Statements above and Part II, Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations Critical Accounting Policies and Estimates in our Annual Report on Form 10-K for the year ended December 31, 2013.

*Recently issued accounting pronouncements*

In April 2014, FASB issued ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for reporting discontinued operations and requires additional disclosures about discontinued operations. The ASU requires an entity to report as a discontinued operation only a disposal that represents a strategic shift in its operations that has a major effect on its operational and financial results. The ASU will be effective for us beginning January 1, 2015, including interim periods in our fiscal year 2015, and does not allow for retrospective adoption. Early application is permitted, but only for those disposals (or classifications as held-for-sale) that have not been reported in financial statements previously issued or available for issuance. We do not expect the adoption of this update to have a material impact on our consolidated results of operations, cash flows, financial position or disclosures.

In May 2014, the FASB issued Accounting Standards Update ( ASU ) No. 2014-09, Revenue from Contracts with Customers, which will replace most existing revenue recognition guidance in U.S. GAAP. The core principle of the ASU is that an entity should recognize revenue for the transfer of goods or services equal to the amount that it expects to be entitled to receive for those goods or services. The ASU requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments. The ASU will be effective for us beginning January 1, 2017, including interim periods in our fiscal year 2017, and allows for both retrospective and prospective adoption. We are in the process of determining the method of adoption and assessing the impact of this ASU on our consolidated results of operations, cash flows, financial position or disclosures.

In June 2014, FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved after the Requisite Service Period, which requires an entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition. The ASU will be effective for us beginning January 1, 2016, including interim periods in our fiscal year 2016. Early adoption and retrospective application are permitted. We do not expect the adoption of this update to have a material impact on our consolidated results of operations, cash flows, financial position or disclosures.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

During the nine months ended September 30, 2014, there were no material changes in our market risk exposure. For a discussion of our market risk associated with foreign currency risk, interest rate risk and credit risk, see Part II, item 7A Quantitative and Qualitative Disclosures about Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2013.

**Item 4. Controls and Procedures**

*Evaluation of Disclosure Controls and Procedures*

Disclosure controls and procedures are the Company's controls and other procedures which are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 (the Exchange Act) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and the Company's Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b). Based upon that evaluation, the Company's Chief Executive Officer and the Company's Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective in timely alerting them to material information relating to the Company (including its consolidated subsidiaries) required to be included in the Company's periodic SEC filings.

**Table of Contents**

*Changes in Internal Control Over Financial Reporting*

There were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2014 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

In making its assessment of the changes in internal controls over financial reporting during the quarter ended September 30, 2014, our management excluded an evaluation of the disclosure controls and procedures of companies acquired in the nine months ended September 30, 2014. See Note 3 to the Unaudited Consolidated Financial Statements for a discussion of these acquisitions.

**PART II**

**Item 1. Legal Proceedings**

There are no legal proceedings pending against us that we believe are likely to have a material adverse effect on our business, results of operations and financial condition.

**Item 1A. Risk Factors**

We have disclosed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2013 the risk factors that materially affect our business, financial condition or results of operations. You should carefully consider the "Risk Factors" set forth in our Annual Report on Form 10-K for the year ended December 31, 2013, the risk factors set forth in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 and the other information that appears elsewhere in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk facing our Company. Additional risks and uncertainties not currently known to us also may materially adversely affect our business, financial condition and/or results of operations.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

*Unregistered Sales of Equity Securities*

None.

*Use of Proceeds*

None.

*Purchase of Equity Securities by the Issuer and Affiliated Purchasers*

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Table of Contents****Item 5. Other Information**

None.

**Item 6. Exhibits**

- 3.1 Memorandum of Association of the Registrant (incorporated by reference to Exhibit 3.1 to Amendment No. 2 of the Registrant's Registration Statement on Form S-1 (File No. 333-142875) filed with the SEC on July 16, 2007).
- 3.3 Bye-laws of the Registrant (incorporated by reference to Exhibit 3.3 to Amendment No. 4 of the Registrant's Registration Statement on Form S-1 (File No. 333-142875) filed with the SEC on August 1, 2007).
- 31.1 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\*
- 31.2 Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\*
- 32.1 Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\*
- 32.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\*
- 101.INS XBRL Instance Document (1)
- 101.SCH XBRL Taxonomy Extension Schema Document (1)
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document (1)
- 101.DEF XBRL Taxonomy Extension Definition Linkbase Document (1)
- 101.LAB XBRL Taxonomy Extension Label Linkbase Document (1)
- 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document (1)

\* Filed with this Quarterly Report on Form 10-Q.

- (1) Filed with Exhibit 101 to this report are the following documents formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2013 and September 30, 2014, (ii) Consolidated Statements of Income for the three months and nine months ended September 30, 2013 and September 30, 2014, (iii) Consolidated Statements of Comprehensive Income (Loss) for the three months and nine months ended September 30, 2013 and September 30, 2014, (iv) Consolidated Statements of Equity for the nine months ended September 30, 2013 and 2014, (v) Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and September 30, 2014, and (vi) Notes to the Consolidated Financial Statements.

Table of Contents

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 7, 2014

GENPACT LIMITED

By: /s/ N.V. TYAGARAJAN  
**N.V. Tyagarajan**  
**Chief Executive Officer**

By: /s/ EDWARD J. FITZPATRICK  
**Edward J. Fitzpatrick**  
**Chief Financial Officer**

**Table of Contents****EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
3.1	Memorandum of Association of the Registrant (incorporated by reference to Exhibit 3.1 to Amendment No. 2 of the Registrant's Registration Statement on Form S-1 (File No. 333-142875) filed with the SEC on July 16, 2007).
3.3	Bye-laws of the Registrant (incorporated by reference to Exhibit 3.3 to Amendment No. 4 of the Registrant's Registration Statement on Form S-1 (File No. 333-142875) filed with the SEC on August 1, 2007).
31.1	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.2	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS	XBRL Instance Document (1)
101.SCH	XBRL Taxonomy Extension Schema Document (1)
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document (1)
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document (1)
101.LAB	XBRL Taxonomy Extension Label Linkbase Document (1)
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document (1)

\* Filed with this Quarterly Report on Form 10-Q.

(1) Filed with Exhibit 101 to this report are the following documents formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets as of December 31, 2013 and September 30, 2014, (ii) Consolidated Statements of Income for the three months and nine months ended September 30, 2013 and September 30, 2014, (iii) Consolidated Statements of Comprehensive Income (Loss) for the three months and nine months ended September 30, 2013 and September 30, 2014, (iv) Consolidated Statements of Equity for the nine months ended September 30, 2013 and 2014, (v) Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and September 30, 2014, and (vi) Notes to the Consolidated Financial Statements.